

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Schedule 14A Information**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No. 1)**

---

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

**TANGO THERAPEUTICS, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
  - Fee paid previously with preliminary materials.
  - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
-

## EXPLANATORY NOTE

This Amendment No. 1 (this Amended Proxy Statement) amends and restates in its entirety the Definitive Proxy Statement on Schedule 14A of Tango Therapeutics, Inc. (the Company) that was originally filed with the Securities and Exchange Commission on April 21, 2025 (the Original Proxy Statement). This Amended Proxy Statement is being filed for the purpose of correcting the vote required to approve Proposal No. 3, the treatment of abstentions and broker non-votes with respect to Proposal No. 3 and that Proposal No. 3 is a discretionary item. Other than these changes on pages 5 and 45, this Amended Proxy Statement does not otherwise modify or update any other disclosures presented in the Original Proxy Statement.

You should read this Amended Proxy Statement in its entirety and in place of the Original Proxy Statement. The Company will make available to its stockholders this Amended Proxy Statement in lieu of the Original Proxy Statement.



Dear Fellow Stockholder:

Tango Therapeutics was founded with a clear mission: to discover the next generation of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. We made significant progress across our research and clinical development programs in 2024 and early 2025:

- In November 2024, we reported positive early data from the ongoing Phase 1/2 clinical trial of TNG462, our lead PRMT5 inhibitor, demonstrating durable clinical activity across multiple cancer types, with a strong safety and tolerability profile. We have initiated a robust clinical development program for TNG462.
- In November 2024, we also announced data from the Phase 1/2 clinical trial of TNG908, our first brain-penetrant PRMT5 inhibitor. TNG908 demonstrated clinical activity and was well-tolerated in non-CNS solid tumors. However, TNG908 did not meet the pharmacokinetic exposure threshold for clinical efficacy in glioblastoma and, therefore, we decided to discontinue further development in TNG908 to focus our resources on TNG462 and TNG456, our next generation brain-penetrant PRMT5 inhibitor being developed for glioblastoma.
- In January 2025, the U.S. Food and Drug Administration, or FDA, cleared the Investigational New Drug, or IND, application for TNG45.
- TNG260, our first-in-class CoREST inhibitor, demonstrated a favorable safety, tolerability, and pharmacokinetic profile in dose escalation, and we have established clinical proof-of-mechanism based on pharmacodynamic data from on-treatment patient biopsies. We are now enrolling lung cancer patients in the dose expansion portion of our Phase 1 study.

The board of directors and I are pleased to invite you to attend the 2025 Annual Meeting of Stockholders, or the Annual Meeting, of Tango Therapeutics, Inc., or Tango, or the Company, to be held virtually on Wednesday, June 5, 2025 at 9:00 a.m. Eastern Time. Stockholders will have the ability to participate in the Annual Meeting, vote their shares and ask questions by accessing the virtual meeting.

At the Annual Meeting, our stockholders will be asked to: (1) elect one nominee who is named in the Proxy Statement as a Class I Director; (2) ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; (3) approve an amendment to our

---

amended and restated certificate of incorporation, as amended to date, to increase to the number of shares of authorized common stock from 200,000,000 to 400,000,000; (3) hold a non-binding, advisory vote to approve the compensation of our named executive officers; (4) hold a non-binding, advisory vote on the frequency of further non-binding, advisory votes on the compensation of our named executive officers; and (5) transact any other business that properly comes before the Annual Meeting (including adjournments, continuations and postponements thereof). Our board of directors recommends that you vote "FOR" the election of the director nominee, "FOR" the ratification of the appointment of PricewaterhouseCoopers LLP, "FOR" the amendment to our amended and restated certificate of incorporation, as amended to date, to increase the number of shares of authorized common stock, "FOR" the compensation of our named executive officers and "FOR" the option of once every "one year" as the preferred frequency of future non-binding, advisory votes on the compensation of our named executive officers. You should carefully read our proxy materials, which contain detailed information concerning each of these proposals.

Under the Securities and Exchange Commission rules, the Company is providing access to the proxy materials for the Annual Meeting to stockholders via the Internet. Accordingly, you can access the proxy materials and vote at [www.proxyvote.com](http://www.proxyvote.com). Instructions for accessing the proxy materials and voting are described below and in the Notice of Internet Availability of Proxy Materials that you received in the mail (unless you have previously requested a paper copy of our proxy materials). The Notice of Internet Availability of Proxy Materials also contains instructions on how to request a paper copy of our proxy materials and our Annual Report on Form 10-K for the year ended December 31, 2024. This process allows us to provide our stockholders with the information they need on a more timely basis, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials.

Your vote is very important. Whether or not you plan to virtually attend the meeting, please carefully review the proxy materials and then cast your vote. If you are a stockholder of record and have received our Notice of Internet Availability of Proxy Materials, then instructions regarding how you can vote are contained in that notice. If you requested to receive a printed set of the proxy materials, please vote by completing, signing, dating and mailing the accompanying proxy card in the return envelope or voting by telephone or the Internet, in accordance with the instructions set forth on the proxy card. Submitting your vote via the Internet or by telephone or proxy card will not affect your right to attend and to vote at the Annual Meeting if you decide to virtually attend the Annual Meeting. If your shares are held in street name (held for your account by a broker or other nominee), you will receive instructions from your broker or other nominee explaining how to vote your shares, and you will have the option to cast your vote by telephone or over the Internet if your voting instruction form from your broker or nominee includes instructions and a toll-free telephone number or Internet website to do so. In any event, to be sure that your vote will be received in time, please cast your vote by your choice of available means at your earliest convenience.

On behalf of our board of directors, team members, and patients, thank you for your ongoing support of, and continued interest in, Tango.

Sincerely,



Barbara Weber, M.D.  
*President and Chief Executive Officer*

---



**Tango Therapeutics, Inc.**  
201 Brookline Avenue, Suite 901  
Boston, MA 02215

**NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS**  
**To be held on June 5, 2025**

Notice is hereby given that the 2025 Annual Meeting of Stockholders, or Annual Meeting, of Tango Therapeutics, Inc., will be held online on Thursday, June 5, 2025. You may attend the meeting virtually via the Internet, where you will be able to participate in the meeting, vote electronically and submit questions that are germane to the matters under consideration at the Annual Meeting. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials, your proxy card (if you received a printed copy of the proxy materials) or in the instructions that accompanied your proxy materials in order to attend the Annual Meeting.

The purpose of the Annual Meeting is the following:

1. To elect one Class I Director, Lesley Ann Calhoun, to our board of directors, to serve until the 2028 annual meeting of stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation or removal;
2. To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025;
3. To approve an amendment to our Second Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000;
4. To approve, on a non-binding, advisory basis, the compensation of our named executive officers;
5. To vote on a non-binding, advisory basis, on the frequency of future non-binding, advisory votes on executive compensation; and
6. To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

The Annual Meeting will begin promptly at 9:00 a.m. Eastern Time. Only stockholders of record at the close of business on April 8, 2025 will be entitled to vote at the Annual Meeting and any adjournment or postponement thereof.

We are pleased to adhere to the Securities and Exchange Commission's "Notice and Access" rule that allows companies to furnish their proxy materials by posting them on the Internet. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials, or the Notice, instead of a paper copy of the accompanying proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or 2024 Annual Report. We plan to mail the Notice on or about April 21, 2025, and it contains instructions on how to access both the 2024 Annual Report and accompanying proxy statement over the Internet. This method provides our stockholders with expedited access to proxy materials and not only lowers the cost of printing and distribution but also reduces the environmental impact of the Annual Meeting. If you would like to receive a print version of the proxy materials, free of charge, please follow the instructions in this Notice.

To be virtually admitted to the Annual Meeting and vote your shares, you must provide the 16-digit control number as provided in the Notice, your proxy card (if you received a printed copy of the proxy materials) or in the instructions that accompanied your proxy materials. Please see the "General Information Regarding the Meeting"

---

section of the proxy statement that accompanies this notice for more details regarding the logistics of the virtual Annual Meeting, including the ability of stockholders to submit questions that are germane to the topics under consideration at the Annual Meeting during the Annual Meeting, and technical details and support related to accessing the virtual platform.

Your vote is important. Whether or not you expect to attend the Annual Meeting virtually, it is important that your shares be represented. To ensure that your vote is recorded promptly, please vote as soon as possible, even if you plan to attend the meeting, by submitting your proxy via the Internet at the address listed on the proxy card, via the telephone number listed on the proxy card or by signing, dating and returning the proxy card. Even if you have voted by proxy, you may still vote at the Annual Meeting. Please note, however, that if your shares are held through a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder.

By order of the Board of Directors,

A handwritten signature in blue ink, appearing to read 'D. Barry', is written over the text 'By order of the Board of Directors,'.

Douglas Barry

Chief Legal Officer, Chief Compliance Officer and Corporate Secretary

Boston, MA  
April 21, 2025

---

## TABLE OF CONTENTS

	Page
<a href="#">Proxy Statement Summary</a>	1
<a href="#">General Information Regarding the Meeting</a>	2
<a href="#">Overview of Proposals</a>	8
<a href="#">Proposal No. 1 – Election of Class I Director</a>	9
<a href="#">General Information About the Board of Directors</a>	10
<a href="#">Corporate Governance</a>	13
<a href="#">General Information About the Executive Officers</a>	18
<a href="#">Compensation Discussion and Analysis</a>	18
<a href="#">Non-Employee Director Compensation</a>	39
<a href="#">Report of the Compensation Committee</a>	41
<a href="#">Proposal No. 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm</a>	41
<a href="#">Principal Accountant Fees and Services</a>	42
<a href="#">Report of the Audit Committee</a>	43
<a href="#">Proposal No. 3 - Vote to Amend the Second Amended and Restated Certificate of Incorporation to increase the Number of Authorized Shares of Common Stock</a>	44
<a href="#">Proposal No. 4 - Non-Binding Advisory Vote To Approve Named Executive Officer Compensation</a>	46
<a href="#">Proposal No. 5 - Non-Binding, Advisory Vote On The Preferred Frequency Of Future Advisory Votes On Named Executive Officers Compensation</a>	47
<a href="#">Security Ownership of Certain Beneficial Owners and Management</a>	48
<a href="#">Certain Relationships and Related Party Transactions</a>	50
<a href="#">Additional Information and Other Business</a>	52
<a href="#">Annex A</a>	

---



## PROXY STATEMENT SUMMARY

### FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 5, 2025

This proxy statement contains information about the 2025 Annual Meeting of Stockholders, or the Annual Meeting, of Tango Therapeutics, Inc., which will be held online on June 5, 2025 at 9:00 a.m. Eastern Time. You may attend the Annual Meeting virtually via the Internet at [www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025), where you will be able to vote electronically and submit questions germane to the matters under consideration at the Annual Meeting. The board of directors of Tango Therapeutics, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms “Tango,” the “Company,” “we,” “us,” and “our” refer to Tango Therapeutics, Inc. The mailing address of our principal executive office is: 201 Brookline Avenue, Suite 901, Boston, Massachusetts, 02215.

All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If a proxy is signed and/or returned without instructions, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice to that effect, by mailing a duly executed proxy bearing a later date, re-voting by phone or the Internet prior to the date and time identified in this proxy statement or by voting in person at the Annual Meeting. We are mailing to our stockholders a Notice of Internet Availability of proxy materials, or the Notice, and our 2024 Annual Report on or about April 21, 2025.

#### **Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on June 5, 2025:**

*This proxy statement and our 2024 Annual Report on Form 10-K are  
available for viewing, printing and downloading at [www.proxyvote.com](http://www.proxyvote.com).*

**A copy of our 2024 Annual Report on Form 10-K, as filed with the Securities Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written request or oral request to Tango Therapeutics, Inc., 201 Brookline Avenue, Suite 901, Boston, Massachusetts, 02215, (857) 320-4900, Attention: Corporate Secretary. This proxy statement and our 2024 Annual Report are also available on the SEC’s website at [www.sec.gov](http://www.sec.gov).**

## GENERAL INFORMATION REGARDING THE MEETING

### **Why is Tango holding a virtual Annual Meeting?**

This year's Annual Meeting will be a "virtual meeting" of stockholders. We believe that the virtual meeting format facilitates greater stockholder attendance and participation at our Annual Meeting by allowing all stockholders to participate equally through the Internet, free of cost. Stockholders will, to the extent possible, be afforded rights and opportunities to participate at the virtual meeting similar to those they would have at an in-person meeting. We have designed our virtual format to enhance, rather than constrain, stockholder access, participation and communication.

### **How can I virtually attend the Annual Meeting?**

To attend and participate in the Annual Meeting, stockholders will need to access the live webcast of the meeting. To do so, stockholders will need to visit [www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025) and enter the 16-digit control number provided in the Notice of Internet Availability of the Proxy Materials, or the Notice, the proxy card (if the stockholder received a printed copy of the proxy materials) or in the instructions that accompanied the stockholders' proxy materials. Beneficial owners of shares held in "street name" (as described below) will need to follow the instructions provided in the voting instructions form by their broker, bank or other nominee that holds their shares.

On the day of the Annual Meeting, stockholders may log-in to the online virtual annual meeting platform beginning at 8:45 a.m. Eastern Time, and the meeting will begin promptly at 9:00 a.m. Eastern Time. Please allow ample time for on-line login so that you may participate in the entire Annual Meeting.

Questions related to substantive matters of business under consideration at the Annual Meeting may be asked during the Annual Meeting by logging on to the virtual meeting platform. If you wish to submit a question during the Annual Meeting, you may do so on the virtual meeting platform [www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025). Our Annual Meeting will be governed by the Annual Meeting's Rules of Conduct and Procedures, which will address the ability of stockholders to ask questions during the meeting and rules for how questions will be recognized and addressed. The Annual Meeting's Rules of Conduct and Procedures will be available on the virtual meeting platform during the course of the Annual Meeting. Any questions or comments that are unrelated to the business of the Annual Meeting will not be addressed at the meeting.

### **How can I get help if I have trouble checking in or listening to the meeting online?**

We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting or submitting questions. If you encounter any difficulties accessing the virtual meeting or submitting a question, a technical support number will be posted on the virtual meeting platform ([www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025)), which may be accessed beginning 15 minutes prior to the scheduled start time of the Annual Meeting.

### **When are this proxy statement and the accompanying materials scheduled to be sent to stockholders?**

We are mailing to our stockholders a Notice instead of a paper copy of the accompanying proxy statement and our 2024 Annual Report on or about April 21, 2025, and it contains instructions on how to access those documents over the Internet. You will need the control number included on the Notice, proxy card or voting instruction form to access these materials. If you would like to receive a print version of the proxy materials, free of charge, please follow the instructions on the Notice.

### **Who is soliciting my vote?**

Our board of directors is soliciting your vote for the Annual Meeting, including at any adjournments or postponements of the meeting.

### **When is the record date for the Annual Meeting?**

The record date for determination of stockholders entitled to vote at the Annual Meeting is the close of business on April 8, 2025. Only stockholders of record at the close of business on April 8, 2025 are entitled to notice of and to vote at the Annual Meeting and any adjournment or postponement of the meeting.

### **How many votes can be cast by all stockholders?**

There were 108,107,890 shares of our voting common stock, par value \$0.001 per share, outstanding on April 8, 2025, all of which are entitled to vote with respect to all matters to be acted upon at the Annual Meeting. Each stockholder of record is entitled to one vote for each share of our common stock held by such stockholder. As the stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or vote on your own behalf at our virtual Annual Meeting. None of our authorized shares of preferred stock were outstanding as of April 8, 2025.

### **Who is entitled to vote?**

*Registered Stockholders.* If shares of our common stock are registered directly in your name with our transfer agent, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or vote on your own behalf at our virtual Annual Meeting. Throughout this proxy statement, we refer to these registered stockholders as “stockholders of record.”

*Street Name Stockholders.* If shares of our common stock are held on your behalf in a brokerage account or by a bank or other nominee, you are considered to be the beneficial owner of shares that are held in “street name,” and the proxy materials were forwarded to you by your broker or nominee, who is considered the stockholder of record with respect to those shares. As the beneficial owner, you have the right to direct your broker, bank or other nominee as to how to vote your shares. Beneficial owners are also invited to attend our virtual Annual Meeting. If your shares are held in “street name”, you will receive instructions from your bank, broker or other nominee explaining how to vote your shares, and you will have the option to cast your vote by telephone or over the Internet if your voting instruction form from your bank, broker or nominee includes instructions and a toll-free telephone number or Internet website to do so. Note that if your shares are held in “street name,” you should also be receiving a voting instruction form for you to use from your broker. Throughout this proxy statement, we refer to stockholders who hold their shares through a bank, broker, bank or other nominee as “street name stockholders.”

### **What matters are being voted on at the Annual Meeting?**

The following matters are being voted on at the Annual Meeting:

- (1) Elect one director, Lesley Ann Calhoun, as a Class I Director of the board of directors, to serve until the 2028 annual meeting of stockholders and until her successor has been duly elected and qualified.
- (2) Ratify the appointment of PricewaterhouseCoopers LLP as Tango's independent registered public accounting firm for 2025.
- (3) Approve an amendment to our Second Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000;
- (4) To hold a non-binding, advisory vote to approve the compensation of our named executive officers; and
- (5) To hold a non-binding, advisory vote on the frequency of future non-binding, advisory votes on executive compensation.

We do not know of any other matters that may come before the Annual Meeting. If any other matters are properly presented at the Annual Meeting, your form of proxy authorizes the individuals named as proxies to vote, or otherwise act, in accordance with their best judgment.

### **How do I vote?**

If you are a stockholder of record, there are four ways to vote:

- **By Internet.** You may vote at [www.proxyvote.com](http://www.proxyvote.com), 24 hours a day, seven days a week. You will need the control number included on your Notice or proxy card in order to vote by Internet.
- **During the Annual Meeting.** You may vote in person virtually by attending the Annual Meeting through [www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025). To attend the Annual Meeting virtually and vote your shares, you must register for the Annual Meeting and provide the control number located on your Notice or proxy card.
- **By Telephone.** You may vote using a touch-tone telephone by calling 1-800-690-6903, 24 hours a day, seven days a week. You will need the control number included on your Notice or proxy card to vote by telephone.

- **By Mail.** You may vote by completing and mailing your proxy card.

Even if you plan to participate in our virtual Annual Meeting, we recommend that you vote by proxy in advance of the Annual Meeting date so that your vote will be counted if you later decide not to participate in the Annual Meeting.

If you are a street name stockholder, you will receive voting instructions from your broker, bank or other nominee. You must follow the voting instructions provided by your broker, bank or other nominee in order to instruct your broker, bank or other nominee on how to vote your shares. Street name stockholders should generally be able to vote by returning an instruction card, or by telephone or on the Internet. However, the availability of telephone and Internet voting will depend on the voting process of your broker, bank or other nominee. As discussed above, if you are a street name stockholder, you may not vote your shares on your own behalf at the Annual Meeting unless you obtain a legal proxy from your broker, bank or other nominee.

### ***By Proxy***

If you will not be attending the Annual Meeting, you may vote by proxy. You can vote by proxy over the Internet or telephone by following the instructions provided in the enclosed proxy card. Proxies submitted by mail must be received by the deadline set forth on the proxy card.

If you complete and submit your proxy before the Annual Meeting, the persons named as proxies will vote the shares represented by your proxy in accordance with your instructions. If you submit a signed proxy without giving voting instructions, your shares will be voted in the manner recommended by the board of directors on all matters presented in this proxy statement, and as the persons named as proxies may determine in their discretion with respect to any other matters properly presented at the Annual Meeting. You may also authorize another person or persons to act for you as proxy in a writing, signed by you or your authorized representative, specifying the details of those proxies' authority. The original writing must be given to each of the named proxies, although it may be sent to them by electronic transmission if, from that transmission, it can be determined that the transmission was authorized by you.

If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting additional proxies), the persons named in your proxy and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual Meeting.

### **How do I change or revoke my vote or proxy?**

You may revoke your proxy by (1) entering a new vote by mail, over the Internet or via telephone that we receive before the start of the Annual Meeting, (2) attending and voting at the Annual Meeting online (although attendance at the Annual Meeting will not in and of itself revoke a proxy), or (3) by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with our Corporate Secretary. Any written notice of revocation or subsequent proxy card must be received by our Corporate Secretary prior to the taking of the vote at the Annual Meeting. Such written notice of revocation or subsequent proxy card should be hand delivered to our Corporate Secretary or sent to our principal executive offices at 201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215, Attention: Corporate Secretary. Only your latest vote will be counted at the Annual Meeting.

If a broker, bank, or other nominee holds your shares, you must contact such broker, bank, or nominee in order to find out how to change your vote.

### **How is a quorum reached?**

Our Amended and Restated Bylaws, or bylaws, provide that a majority of the shares entitled to vote, present or represented by proxy, will constitute a quorum for the transaction of business at the Annual Meeting.

Under the General Corporation Law of the State of Delaware, shares that are voted "abstain" or "withheld" and broker "non-votes" are counted for purposes of determining whether a quorum is present at the Annual Meeting. If a quorum is not present, the meeting may be adjourned until a quorum is obtained. There were 108,107,890 shares of common stock outstanding and entitled to vote on April 8, 2025, our record date. Therefore, a quorum will be present if 54,053,946 shares of our common stock are present in person or represented by executed proxies timely received by us at the Annual Meeting.

**What vote is required for each proposal?**

		<i>Board's Recommendation</i>	<i>Broker Discretionary Voting Allowed</i>	<i>Treatment of Votes Withheld, Abstentions and Broker Non-Votes</i>	<i>Required</i>
Proposal 1	Election of Class I Director	FOR Class I Director Nominee (Lesley Ann Calhoun)	No	Votes withheld and broker non-votes, if any, will have no effect on the outcome of the proposal	Plurality of votes properly cast
Proposal 2	Ratification of PricewaterhouseCoopers LLP as independent auditors for 2025	FOR	Yes	Abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal	Majority of votes properly cast
Proposal 3	Approval of amendment to our Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock	FOR	Yes	Abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal	Majority of votes cast
Proposal 4	Approval, on a non-binding, advisory basis, of the compensation of our named executive officers	FOR	No	Abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal	Majority of votes properly cast
Proposal 5	Non-binding, advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers	1 Year	No	Abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal	Highest number of affirmative votes properly cast

**How is the vote counted?**

Under our bylaws, any proposal other than an election of directors is decided by a majority of the votes properly cast for and against such proposal, except where a larger vote is required by law, our bylaws, or by our Second Amended and Restated Certificate of Incorporation, as amended to date, or charter. As noted above, abstentions and broker “non-votes” are not included in the tabulation of the voting results on any such proposal and, therefore, do not have an impact on such proposals. A broker “non-vote” occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item, and has not received instructions from the beneficial owner.

If your shares are held in “street name” by a brokerage firm, your brokerage firm is required to vote your shares according to your instructions. If you do not give instructions to your brokerage firm, the brokerage firm will still be able to vote your shares with respect to certain “discretionary” items, but will not be allowed to vote your shares with respect to “non-discretionary” items. Proposal No. 1, Proposal No. 4 and Proposal 5 are “non-discretionary” items. If you do not instruct your broker how to vote with respect to these proposals, your broker may not vote for these proposals, and those votes will be counted as broker “non-votes.” Proposal No. 2 and Proposal No. 3 are considered to be a discretionary items, and your brokerage firm will be able to vote on these proposals even if it does not receive instructions from you.

To be approved, the proposal for the amendment to our charter must receive an affirmative vote by the majority of the votes cast. Abstentions and broker non-votes, if any, will have no effect on the outcome of Proposal No. 3.

To be elected, the director nominated via Proposal No. 1 must receive a plurality of the votes properly cast and entitled to vote on the proposal, meaning that the director nominee receiving the most votes will be elected (even if it is less than a majority of the votes cast). You may vote for the director nominee or withhold authority to vote your shares. Shares voting “withheld” have no effect on the election of the director. Broker non-votes will have no effect on the election of the nominee for Class I Director.

The non-binding, advisory vote to approve the compensation of our named executive officers, or the say-on-pay vote, is a “non-routine” matter. If you do not instruct your broker how to vote with respect to this proposal, your broker may not vote for this proposal, and those votes will be counted as broker “non-votes.” For this proposal, a majority of the votes properly cast thereon is required to approve on a non-binding, advisory basis, the compensation of the Company’s named executive officers. Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal. Because this vote is advisory and not binding on us, our board of directors or our compensation committee in any way, our board of directors and compensation committee may decide that it is in our and our stockholders’ best interests to compensate our named executive officers in an amount or manner that differs from what is approved by our stockholders, but our board of directors and compensation committee will take into account the outcome of the vote when considering future executive compensation matters.

The non-binding, advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers, or the say-on-frequency vote, is a “non-routine” matter. If you do not instruct your broker how to vote with respect to this proposal, your broker may not vote for this proposal, and those votes will be counted as broker “non-votes.” For this proposal, stockholders will not be voting to approve or disapprove of the recommendation of our board of directors on the preferred frequency of future non-binding, advisory votes on the compensation of our named executive officers. The proxy card provides stockholders with the opportunity to choose among four options with respect to this proposal (holding the vote every one, two, or three years, or abstaining). The option that receives the highest number of affirmative votes properly cast will be deemed to be the frequency preferred by our stockholders. Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal. The vote required, and the method of calculation, for each proposal at the Annual Meeting is described above.

#### **Who pays the cost for soliciting proxies?**

We are making this solicitation and will pay the entire cost of preparing and distributing our proxy materials and soliciting votes. If you choose to access the proxy materials or vote over the Internet, you are responsible for any Internet access charges that you may incur. Our officers and employees may, without compensation other than their regular compensation, solicit proxies through further mailings, personal conversations, facsimile transmissions, e-mails, or otherwise. Proxy solicitation expenses that we will pay include those for preparation, mailing, returning, and tabulating the proxies.

#### **How may stockholders submit matters for consideration at an Annual Meeting?**

The required notice must be in writing and received by our Corporate Secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the preceding year’s annual meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A) the 90th day prior to such annual meeting and (B) the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2026 Annual Meeting of Stockholders, the required notice must be received by our Corporate Secretary at our principal executive offices no earlier than February 5, 2026 and no later than March 7, 2026. See the section titled “*Stockholder Proposals*.”

In addition, any stockholder proposal intended to be included in the proxy statement for the next annual meeting of our stockholders in 2026 must also satisfy the requirements of SEC Rule 14a-8 under the Exchange Act, and be received not later than December 22, 2025. In addition, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act. If the date of the annual meeting is moved by more than 30 days from the date contemplated at the time of the previous year’s proxy statement, then notice must be received within a reasonable time before we begin to print and send proxy materials. If that happens, we will publicly announce the deadline for submitting a proposal in a press release or in a document filed with the SEC.

If a stockholder wishes to propose a nomination of persons for election to our board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our Corporate Secretary of the stockholder’s intention to bring such business before the meeting.

#### **How can I find out the results of the voting at the Annual Meeting?**

We plan to announce preliminary voting results at the Annual Meeting. Final voting results will be published in a Current Report on Form 8-K, or Form 8-K, that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.

## OVERVIEW OF PROPOSALS

The summary below highlights information that is described in more detail elsewhere in this proxy statement. This summary does not contain all of the information you should consider, and we urge you to read the entire proxy statement carefully before voting.

This Proxy Statement contains four proposals requiring stockholder action.

### **Proposal No. 1 - Election of Class I Director**

You are being asked to vote on the election of one Class I Director, Lesley Ann Calhoun, to our board of directors.

### **Proposal No. 2 - Ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm**

You are being asked to vote to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

### **Proposal No. 3 – Approval of an Amendment to our Second Amended and Restated Certificate of Incorporation**

You are being asked to vote to approve an amendment to our Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock.

### **Proposal No. 4 – Non-binding, advisory vote on the compensation of our named executive officers**

You are being asked to vote on a non-binding, advisory basis, to approve the compensation of our named executive officers.

### **Proposal No. 5 – Non-binding, advisory vote on the frequency of future advisory votes on executive compensation**

You are being asked to vote on a non-binding, advisory basis, on the frequency of future advisory votes on executive compensation.

The board of directors recommends that you vote **FOR** the director nominee in Proposal 1 and **FOR** Proposal No. 2, Proposal No. 3, and Proposal No. 4. The board of directors unanimously recommends a vote, on a non-binding, advisory basis, for “**ONE YEAR**” as the preferred frequency for future non-binding, advisory votes on the compensation of our named executed officers.

Each of the proposals listed above is discussed in more detail in the pages that follow.

## PROPOSAL NO. 1 – ELECTION OF CLASS I DIRECTOR

Our board of directors currently consists of seven members. In accordance with the terms of our charter and bylaws, our board of directors is divided into three classes – Class I, Class II and Class III – with members of each class serving staggered three-year terms.

One director has been nominated for election at the Annual Meeting to serve until the 2028 annual meeting of stockholders and until her successor has been duly elected and qualified. In the event the nominee is unable to serve as a director, the shares represented by the proxy will be voted for such other candidate, if any, who is nominated by the board of directors to replace the nominee. The nominee has consented to be named in the proxy statement and has indicated her intent to serve if elected. The board of directors has no reason to believe that the nominee will be unable to serve. Pursuant to our bylaws, directors are elected by plurality vote in uncontested director elections such as this one. The number of candidates for election as Class I Directors at the Annual Meeting is the same as the number of Class I Directors to be elected at the Annual Meeting. Therefore, this is an uncontested election and the director will be elected by the affirmative vote of a plurality of the votes properly cast by the shares present or represented and entitled to vote at the Annual Meeting, in person or by proxy. The nominee for election as director is identified in this proxy statement.

The following table presents our current directors, their respective term on the board of directors, ages and positions as of April 8, 2025. Director service dates in the table below and elsewhere in this proxy statement reflect the periods such director commenced director service with Tango prior to the completion of the Business Combination (as described below).

Name	Age	Position	Served as a Director Since
<b>Class I Directors with terms that will expire at the Annual Meeting</b>			
Lesley Ann Calhoun	59	Director	March 2021
<b>Class II Directors with terms that will expire at the 2026 Annual Meeting</b>			
Malte Peters, M.D.	62	Director	September 2018
Mace Rothenberg, M.D.	68	Director	March 2021
Kanishka Pothula	40	Director	November 2023
<b>Class III Directors with terms that will expire at the 2027 Annual Meeting</b>			
Alexis Borisy	53	Director and Chairman of the Board	March 2017
John Ketchum	69	Director	August 2023
Barbara Weber, M.D.	68	President, Chief Executive Officer and Director	March 2017

Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires.

### Nominee for Election as Class I Director

Our board of directors has nominated Lesley Ann Calhoun for election as a Class I Director to serve for a three-year term ending at the 2028 annual meeting of stockholders and until her successor is elected and qualified. Ms. Calhoun is a current member of our board of directors and has consented to serve if elected.

### Vote Required and Board of Directors' Recommendation

Each stockholder has one vote per share. Stockholders do not have the right to vote cumulatively in electing directors.

The nominee for Class I Director who receives the most votes (also known as a plurality) will be elected. You may vote either FOR the nominee or WITHHOLD your vote from the nominee. Shares voting “withheld” will have no effect on the election of a director. If your shares are held in “street name” by a broker, bank or other nominee, your broker, bank or other nominee does not have authority to vote your unvoted shares held by the firm for the election of a director. As a result, any shares not voted by you will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.

The proxies will be voted in favor of the above nominee unless a contrary specification is made in the proxy. The nominee has consented to serve as our director if elected. However, if the nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as our board of directors may designate.

**The board of directors recommends voting “FOR” the election of Lesley Ann Calhoun as a Class I Director, to serve for a three-year term ending at the annual meeting of stockholders to be held in 2028.**

## GENERAL INFORMATION ABOUT THE BOARD OF DIRECTORS

### Our Board of Directors

On August 10, 2021, BCTG Acquisition Corp., a Delaware corporation, or BCTG, consummated a business combination, or Business Combination, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation and Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc., which we refer to as “Tango” in this proxy statement prior to the closing of the Business Combination). Upon the consummation of the Business Combination, our board of directors was divided into three staggered classes of directors, with each director assigned to one of the three classes. At each annual meeting of our stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the Annual Meeting for the Class I Director, at the annual meeting of stockholders to be held during the year 2026 for Class II Directors and at the annual meeting of stockholders to be held during the year 2027 for Class III Directors. Lesley Ann Calhoun currently serves as our Class I Director, Malte Peters, M.D., Mace Rothenberg, M.D. and Kanishka Pothula currently serve as our Class II Directors and Alexis Borisy, John Ketchum and Barbara Weber, M.D. currently serve as our Class III Directors.

Our charter and bylaws provide that the number of directors shall be fixed solely and exclusively by a resolution adopted from time to time by our board of directors.

### Class I Director Nominee for Election for a Three-Year Term Ending at the 2028 Annual Meeting

*Lesley Ann Calhoun* has served as a member of our board of directors since March 2021. Since June 2020, Ms. Calhoun has served as Executive Vice President and Chief Financial Officer at Aligos Therapeutics, Inc., (NASDAQ: ALGS), or Aligos, a clinical stage biopharmaceutical company; in January 2025, she was also appointed Chief Operating Officer at Aligos. From August 2016 to June 2020, Ms. Calhoun served as Senior Vice President of Finance & Administration and Chief Accounting Officer at Global Blood Therapeutics, Inc. (NASDAQ: GBT). From January 2013 to September 2015, Ms. Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial pharmaceutical company that was acquired by Horizon Pharma plc, a biopharmaceutical company, in May 2015. Ms. Calhoun served as Senior Director of Finance and Corporate Controller at Theravance, Inc. (NASDAQ: TBPH), a biopharmaceutical company, from August 2005 to January 2013. Prior to Theravance, Ms. Calhoun held various senior finance positions of increasing responsibility where she oversaw all aspects of finance and accounting operations for U.S. and multinational, publicly-traded and pre-IPO stage technology companies and companies in the biopharmaceutical industry. Earlier in her career, Ms. Calhoun was a member of the audit practice of Deloitte & Touche LLP from 1989 to 2001. Ms. Calhoun holds a B.S. in business administration with a concentration in accounting from San Francisco State University and is a Certified Public Accountant (inactive). We believe that Ms. Calhoun’s financial and accounting expertise and her experience in the finance and life sciences industries qualify her to serve as a member of our board of directors.

### Class II Directors Continuing in Office Until the 2026 Annual Meeting

*Malte Peters, M.D.*, has served on our board of directors since September 2018. Dr. Peters has been Chief Executive Officer of HOOKIPA Pharma Inc. (NASDAQ: HOOK), or HOOKIPA, a clinical stage biopharmaceutical company, since July 2024. In December 2022, Dr. Peters joined the board of directors of HOOKIPA, where he also served as an interim Senior Clinical Advisor from November 2023 to July 2024. From March 2020 to December 2022, Dr. Peters served as Chief Research and Development Officer of MorphoSys AG, a biopharmaceutical company, and prior to that served as its Chief Development Officer and member of its management board since March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. From 2004 to 2015, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Dr. Peters has also held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany, served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at Micromet AG. Dr. Peters received his Doctor of Medicine from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany. After scientific work at different universities, he habilitated in Internal Medicine at the University of Mainz, Germany. We believe Dr. Peters’s extensive knowledge of the biotechnology industry makes him qualified to serve on our board of directors.

*Mace Rothenberg, M.D.*, has served on our board of directors since March 2021. Dr. Rothenberg currently serves as the President and Executive Director of the Museum of Medicine and Biomedical Discovery, a position he has held since September 2022. Dr. Rothenberg was previously at Pfizer, Inc., a pharmaceutical company, where he served as Chief Medical Officer and Head of Worldwide Medical and Safety from 2019 to 2021, Chief Development Officer for Oncology from 2016 to 2018, and Senior Vice President for Clinical

Development and Medical Affairs for Pfizer Oncology from 2008 to 2016. Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia, serving on the faculties of the University of Texas Health Science Center — San Antonio and Vanderbilt University Medical Center. Dr. Rothenberg is a fellow of the American College of Physicians and the American Society of Clinical Oncology and is board-certified in Internal Medicine and Medical Oncology. Dr. Rothenberg has been a member of the board of directors of Surrozen, Inc. (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, since May 2021, Aulos Bioscience, a privately-held immuno-oncology company, since March 2021, and Chiara Biosciences, a privately-held biotechnology company, since January 2023. Dr. Rothenberg received his B.A. from the University of Pennsylvania and his M.D. from the New York University School of Medicine. He completed his residency in Internal Medicine at Vanderbilt University and his fellowship in Medical Oncology at the National Cancer Institute. We believe Dr. Rothenberg's industry experience and life science expertise make him qualified to serve on our board of directors.

*Kanishka Pothula* has served as a member of our board of directors since November 2023. Mr. Pothula joined Nextech Ventures (US), an affiliate of Nextech Invest, in March 2023 and currently serves as a Managing Partner. Prior to joining Nextech Ventures (US), Mr. Pothula spent eleven years at BVF Partners, a biotechnology-focused hedge fund, where he served various roles throughout his tenure, most recently as Managing Partner. Mr. Pothula holds a M.S. in biotechnology from Georgetown University and a B.S. in bioengineering from the University of California, San Diego. We believe that Mr. Pothula's extensive experience in finance and the life sciences industry make him qualified to serve on our board of directors.

### **Class III Directors Continuing in Office Until the 2027 Annual Meeting**

*Alexis Borisy* has served as a member of our board of directors since our founding in 2017 and as the chairman of the board of directors since August 2021. Mr. Borisy is the co-founder and operating chairman of Curie.Bio, a new model for venture in biotech that Mr. Borisy founded in 2022. In 2022, Mr. Borisy co-founded IDRx, Inc., a biopharmaceutical company (which was acquired by GlaxoSmithKline, LLC in February 2025) and did the initial build through Borisy Labs Production, LLC. Also in 2022, Mr. Borisy became a director of Nextech Invest, a Swiss-based venture firm, where he also serves as Chairman. Prior to its acquisition by Revolution Medicines, Inc. (NASDAQ: RVMD), Mr. Borisy served as Chief Executive Officer and Chairman of EQRx, Inc., (formerly NASDAQ: EQRX), a biotechnology company, from June 2019 to November 2023. From 2010 to June 2019, Mr. Borisy was a partner at Third Rock Ventures, a series of venture capital funds investing in life science companies. Mr. Borisy co-founded Blueprint Medicines Corporation (NASDAQ: BPMC), a biopharmaceutical company, and served as its Interim Chief Executive Officer from 2013 to 2014 and has served as a member of its board of directors since 2011. Mr. Borisy co-founded Foundation Medicine, Inc. and served as its Interim Chief Executive Officer from 2009 to 2011 and served as a member of its board of directors from 2009 to July 2018, until its acquisition by Roche. In addition, Mr. Borisy serves as a member of the board of directors of Relay Therapeutics, Inc. (NASDAQ: RLAY), Revolution Medicines, Inc. (NASDAQ: RVMD), and Blueprint Medicines (NASDAQ: BPMC). Mr. Borisy previously served on the board of directors of OPKO Health Inc. (NASDAQ: OPKO) and Magenta Therapeutics (formerly NASDAQ: MGTA, prior to its acquisition by Dianthus Therapeutics, Inc.). Mr. Borisy received an A.B. in Chemistry from the University of Chicago and an A.M. in Chemistry and Chemical Biology from Harvard University. We believe Mr. Borisy's extensive experience as an executive of, and working with and serving on the boards of directors of, multiple biopharmaceutical and life sciences companies, his educational background and his experience working in the venture capital industry provide him with the qualifications and skills necessary to serve as a member of our board of directors.

*John Ketchum* has served as a member of our board of directors since August 2023. Since 2018, Mr. Ketchum has operated Bonnieview Consulting, LLC, a consulting agency that provides strategic and business services to pharmaceutical and biotech companies from research and development to full commercialization stages. In 2019, Mr. Ketchum founded, and continues to provide advisory services to, CureLeads, a company that provides a range of services for biomedical firms commercializing specialty drugs in the Middle East and North Africa. From 1996 to 2017, Mr. Ketchum held various positions at Novartis International AG, including as Senior Vice President, Region Head, Emerging Growth Markets from 2014 to 2017 and Senior Vice President, Region Head, Latin America, from 2014 to 2017. Mr. Ketchum serves as an advisor and the Chairman of the Board of Ernest Pharmaceuticals LLC, a privately held oncology company. Mr. Ketchum received his B.A. from Hamilton College and his M.B.A. from the University of North Carolina at Chapel Hill. We believe Mr. Ketchum's industry experience and life science expertise, including his extensive work in commercializing pharmaceuticals in the U.S. and in international markets, make him qualified to serve on our board of directors.

*Barbara Weber, M.D.* has served as our President and Chief Executive Officer since March 2017. Dr. Weber was a Venture Partner at Third Rock Ventures from March 2015 until June 2022, during which time she led the formation of the Company. Previously, Dr. Weber served as Senior Vice President, Oncology Translational Medicine, Novartis from 2009 to 2015, Vice President, Oncology, GSK plc from 2005 to 2009 and Professor, Medicine and Genetics, University of Pennsylvania from 1994 to 2005. Dr. Weber has served on the board of directors of Revolution Medicines, Inc. (NASDAQ: RVMD), a biotechnology company, since April 2018, and FOG Pharma, a private biopharmaceutical company, since October 2018. Dr. Weber served as a director of OPY Acquisition Corp. I (NASDAQ: OHAA), a special purpose acquisition company from October 2021 to December 2023. Dr. Weber received a B.S. in Chemistry and an M.D. from the University of Washington, and was a resident in internal medicine at Yale University and a fellow in Medical Oncology at the

Dana-Farber Cancer Institute. We believe Dr. Weber is qualified to serve on our board based on her position as our President and Chief Executive Officer, her leadership experience and her extensive experience in the biopharmaceutical industry.

#### **Director Independence**

The rules of the Nasdaq market require that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an executive officer or employee of our Company or any other individual having a relationship which, in the opinion of our board of directors, would interfere with the exercise of independent judgement in carrying out the responsibilities of a director. Our board of directors has determined that each individual who serves on our board, other than Dr. Weber, qualifies as an independent director under the rules of Nasdaq and the SEC.

#### **Family Relationships**

There are no family relationships among any of our directors or executive officers.

#### **Adverse Proceedings**

Neither we nor any of our subsidiaries are party to any material proceedings to which any of our directors, officers, affiliates, 5% or more stockholders, or any of their respective associates are a party. We do not believe that any of our directors, officers, affiliates, 5% or more stockholders, or any of their respective associates are adverse to us or any of our subsidiaries or have a material interest that is adverse to us or any of our subsidiaries.

## CORPORATE GOVERNANCE

### Committees of the Board of Directors

Our board of directors has established three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. Each committee operates pursuant to a charter that has been approved and adopted by our board of directors. Each charter is reviewed on an annual basis by the applicable committee and any changes are approved by the board of directors. Each committee charter is posted on our website, [www.tangotx.com](http://www.tangotx.com), under the “Governance” subsection of the “Investors” section. The current members of our audit committee are Lesley Ann Calhoun, Kanishka Pothula and Alexis Borisy; Lesley Ann Calhoun serves as the chairperson of the audit committee. The current members of our compensation committee are Malte Peters, Mace Rothenberg and John Ketchum; Malte Peters is the chairperson of the compensation committee. The current members of our nominating and corporate governance committee are Mace Rothenberg, Kanishka Pothula and Lesley Ann Calhoun; Mace Rothenberg is the chairperson of the nominating and corporate governance committee. Our board of directors reviews the membership of each committee on an annual basis in order to make sure that the legal and regulatory requirements related to committee composition are complied with and that the appropriate set of skills and viewpoints are being brought to the deliberations and decisions of each committee.

During 2024, our board of directors held four meetings. During 2024, all of the directors attended at least 75% of the total number of meetings of the board and committees on which they served. Directors are expected to attend our annual meetings of stockholders, all meetings of the board of directors and all meetings of the committees on which they serve. Five members of the board of directors then in office attended the annual meeting of stockholders on June 5, 2024.

#### *Audit Committee*

The audit committee currently consists of Lesley Ann Calhoun, Kanishka Pothula and Alexis Borisy. Our board has determined that each member of our audit committee is independent under Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. The chairperson of the audit committee is Lesley Ann Calhoun. Our board has determined that Lesley Ann Calhoun is an “audit committee financial expert” within the meaning of SEC regulations. Our board of directors has also determined that each member of the audit committee has the requisite financial expertise required under the applicable requirements of Nasdaq. In arriving at this determination, our board of directors has examined each audit committee member’s scope of experience, familiarity with financial statements and accounting matters through prior exposure at biopharmaceutical companies, and the nature of their employment in the corporate finance sector. The audit committee held four meetings during 2024.

The primary purpose of our audit committee is to discharge the responsibilities of our board of directors with respect to our accounting, financial, and other reporting and internal control practices and to oversee the independent registered accounting firm. Specific responsibilities of our audit committee include:

- helping our board of directors oversee corporate accounting and financial reporting processes;
- managing the selection, engagement and qualifications of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;
- helping to ensure the independence and performance of the independent registered public accounting firm;
- discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;
- developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;
- reviewing policies on financial risk assessment and financial risk management, as well as discussing with management the guidelines and policies that govern the process by which the Company's exposure to risks, including financial, operational, privacy, security, cybersecurity, competition, legal, regulatory, hedging and accounting, is assessed and managed by management;
- reviewing related party transactions;
- obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality-control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and
- approving (or, as permitted, pre-approving) all audit and all permissible non-audit service to be performed by the independent registered public accounting firm.

### ***Compensation Committee***

Our compensation committee currently consists of Malte Peters, Mace Rothenberg and John Ketchum. Our board has determined that each member of our compensation committee is independent under Nasdaq listing standards and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. The chairperson of the compensation committee is Malte Peters. The primary purpose of our compensation committee is to discharge the responsibilities of our board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. The compensation committee held three meetings during 2024.

Specific responsibilities of our compensation committee include:

- reviewing and approving, or recommending that our board approve, the compensation of our executive officers and senior management;
- reviewing and recommending to our board the compensation of our directors;
- administering our stock and equity incentive plans;
- selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the committee’s compensation advisors;
- reviewing, approving, amending and terminating, or recommending that our board approve, amend or terminate, incentive compensation and equity plans, severance agreements, change in control protections and any other compensatory arrangements for our executive officers and other senior management, as appropriate; and
- reviewing and establishing general policies relating to compensation and benefits of our employees.

### ***Compensation Committee Interlocks and Insider Participation***

Dr. Peters, Dr. Rothenberg and Mr. Ketchum served on the compensation committee during the year ended December 31, 2024. None of the members of our compensation committee has at any time been one of our officers or employees or had any relationships with us requiring disclosure under Item 404 of Regulation S-K under the Exchange Act. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee.

### ***Nominating and Corporate Governance Committee***

Our nominating and corporate governance committee currently consists of Mace Rothenberg, Kanishka Pothula, and Lesley Ann Calhoun. Our board has determined each member is independent under Nasdaq listing standards. The chairperson of the nominating and corporate governance committee is Mace Rothenberg. The nominating and corporate governance committee held two meetings during 2024.

Specific responsibilities of our nominating and corporate governance committee include:

- identifying, evaluating and selecting, or recommending that our board approve, nominees for election to our board;
- evaluating the performance of our board and of individual directors;
- evaluating the adequacy of our corporate governance practices and reporting;
- overseeing the environmental, social and governance, or ESG, programs and policies, the scope of risk related to such matters, and the potential risks and liabilities related thereto; and
- developing and making recommendations to our board regarding corporate governance guidelines and matters.

### ***Role of Our Board of Directors in Risk Oversight***

One of the key functions of our board of directors is informed oversight of our risk management process. Our board does not have a standing risk management committee, but rather administers this oversight function directly through our board as a whole, as well as through its standing committees. In particular, our board is responsible for monitoring and assessing strategic risk exposure. Our audit committee oversees the policies and programs relating to our financial and accounting systems, accounting policies, and our internal audit function. It also is responsible for appointing our independent auditor and considering and discussing our major risk exposures (including financial, operational, privacy, security, cybersecurity, competition, legal, regulatory, hedging and accounting) and the steps that the Company’s management has taken to monitor and, to the extent practicable, control such exposures. Our audit committee also monitors

compliance with legal and regulatory requirements and evaluates risk associated with related party transactions. Our compensation committee assesses and monitors whether our compensation plans, policies and programs comply with applicable legal and regulatory requirements and whether our compensation program may encourage excessive risk-taking. Our nominating and corporate governance committee oversees risks related to our governance structure and our environmental, social and governance risk.

Additionally, our board of directors encourages management to promote a culture that incorporates risk management into our day-to-day business operations. Management discusses strategic and operational risks at regular meetings, and throughout the year, reviews these risks with the board of directors as part of management presentations focusing on particular business functions, operations or strategies, including the steps taken by management to mitigate or eliminate such risks.

On an annual basis, the management team conducts an enterprise risk assessment to identify the significant risks related to our corporate operations and strategic goals. This assessment includes meetings with our executive committee and functional leaders throughout the organization, a review with the management team of the most significant risks, the identification of a management team member responsible for oversight of each applicable risk and an overview of risk mitigation procedures (if applicable). The results of the annual enterprise risk assessment are presented to the audit committee.

#### **Separation of the Roles of Chairman and Chief Executive Officer**

Our governing documents permit the roles of chairman of the board and Chief Executive Officer, or CEO, to be filled by the same or different individuals. Our board recognizes that one of its key responsibilities is to periodically evaluate the optimal leadership structure to ensure the board is operating efficiently, effectively, and in the best interests of the Company and its shareholders. The board values the flexibility to determine the optimal model for board leadership at any given time.

At this time, the board has chosen to separate the roles of chairman of the board, held by Alexis Borisy, and CEO, held by Dr. Weber. The board believes that separating these roles is the most appropriate structure for Tango and its shareholders at this time. Separating these positions allows our CEO to focus on our day-to-day business operations and company performance, while the chairman focuses on independent oversight and key strategic decisions while also supporting our supporting our board's oversight of risk and other key governance matters.

#### **Code of Ethics**

We have adopted a Code of Conduct that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The Code of Conduct is available on our website at <https://www.tangotx.com> under "Investors – Governance". Information contained on or accessible through such website is not a part of this proxy statement, and the inclusion of the website address in this proxy statement is an inactive textual reference only.

We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Conduct and disclose any amendments to the Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of Nasdaq, by filing a Form 8-K with the SEC, disclosing such information.

#### **Policy on Trading, Pledging and Hedging of Company Stock**

Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating the risk that a sale may occur at a time when an officer or director is aware of material, non-public information or otherwise is not permitted to trade in Company securities. Our insider trading policy expressly prohibits short sales and derivative transactions of our stock by our executive officers, directors, employees and certain designated consultants and contractors, including short sales of our securities. Our insider trading policy expressly prohibits purchases or sales of puts, calls, or other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership. It is also the policy of the Company to comply with all applicable securities laws when transacting in its own securities. We believe that our policies and procedures are reasonably designed to promote compliance with insider trading laws, any applicable securities laws, rules, regulations and any exchange listing standards.

#### **Director Nomination Process**

In considering candidates for board membership, the nominating and corporate governance committee considers recommendations by: the nominating and corporate governance committee members and other board members; management; our stockholders; third-party search firms; and any other appropriate sources. If a stockholder submits a nominee, the nominating and corporate governance committee will evaluate the qualifications of such stockholder nominee using the same selection criteria the committee uses to evaluate other potential nominees. Our by-laws contain provisions addressing the process by which a stockholder may recommend a person for consideration as a nominee for director at an annual meeting.

Our by-laws provide that stockholders seeking to nominate candidates for election as directors at our annual meeting of stockholders must provide timely notice of their intent in writing. To be timely, a stockholder's written notice will need to be delivered to our principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day prior to the scheduled date of the annual meeting of stockholders. In the event that no annual meeting was held during the preceding year or the annual meeting is advanced more than 30 days before, or more than 60 days after such anniversary date, a timely notice must be received not later than the close of business on the later of the 90th day prior to the scheduled date of such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made. Our bylaws also specify certain requirements as to the form and content of a stockholders' notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

Pursuant to the terms of its charter, the nominating and corporate governance committee requires the following qualifications to be satisfied by any nominee for a position on the board:

- High standards of personal and professional ethics and integrity;
- Proven achievement and competence in the nominee's field and the ability to exercise sound business judgment;
- Skills that are complementary to those of members of the existing board;
- The ability to assist and support management and make significant contributions to the Company's success; and
- An understanding of the fiduciary responsibilities required of a director and a commitment to devote the time and energy necessary to perform those responsibilities.

Our priority in selection of board members is identification of members who will further the interests of our stockholders through their established record of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape. When identifying and evaluating nominees for director, the nominating and corporate governance committee considers, among other factors, the character, integrity, judgment, diversity, independence, skills, education, expertise, business acumen, business judgment, length of service, understanding of Tango's business and industry, conflicts of interest and other requirements.

#### **Stockholder Communications with the Board of Directors**

Any interested party who wishes to communicate with our board of directors or our board chairman may submit a written communication to the attention of such director at the following address:

Tango Therapeutics, Inc.  
201 Brookline Avenue, Suite 901  
Boston, MA 02215

A copy of any such written communication may also be forwarded to Tango's legal counsel and be retained for a reasonable period of time. The director may discuss the matter with Tango's legal counsel, with independent advisors, with non-management directors, or with Tango's management, or may take other action or no action as the director determines in good faith, using reasonable judgment and applying his or her own discretion.

Communications may be forwarded to other directors if they relate to important substantive matters and include suggestions or comments that may be important for other directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we tend to receive repetitive or duplicative communications.

The audit committee oversees the procedures for the receipt, retention, and treatment of complaints received by Tango regarding accounting, internal accounting controls, or audit matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters or potential violations of the federal securities laws. Tango has also established a

toll-free telephone number for the reporting of such activity, which is 1-855-495-2758. Submissions may also be reported online at: <https://www.whistleblowerservices.com/TNGX>.

### **Sustainability**

As we continue to grow and progress as a company, we remain focused on sustainability, including social and environmental, or ESG, issues that affect our stakeholders, which include our future patients, our stockholders, our community and our employees. Our nominating and corporate governance committee has primary oversight over our sustainability efforts.

Our goal is to make the world healthier and improve the lives of patients by developing solutions in drug discovery, cancer biology, functional genomics and translational medicine, pursuing the bold goal of tackling the genetic complexity of cancer.

## GENERAL INFORMATION ABOUT EXECUTIVE OFFICERS

### Executive Officers

The table below identifies and sets forth certain information regarding our executive officers as of April 8, 2025. Officer service dates in the table below and elsewhere in this proxy statement reflect, where applicable, the periods such officer commenced employment with Tango prior to the completion of the Business Combination (as described above).

Name	Age	Position	In Current Position Since
Barbara Weber, M.D.	68	President, Chief Executive Officer and Director	March 2017
Daniella Beckman	46	Chief Financial Officer	September 2019
Adam Crystal, M.D., Ph.D.	48	President of Research and Development	February 2023
Douglas Barry	55	Chief Legal Officer, Chief Compliance Officer and Corporate Secretary	January 2024

See the section of this Proxy Statement captioned "General Information about the Board of Directors" for Dr. Weber's biography.

*Daniella Beckman* has served as our Chief Financial Officer since September 2019 and served as our interim Chief Financial Officer from October 2016 to August 2019. Prior to joining Tango, she provided consulting and interim chief financial officer services for early-stage biotechnology companies from November 2015 to September 2019. Previously, Ms. Beckman was the Chief Financial Officer of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from June 2011 until it was acquired by Merck & Co., Inc., a pharmaceutical company, in August 2014. Ms. Beckman currently serves on the board of directors of Upstream Biopharma (NASDAQ: UPB), a biotechnology company developing treatments for inflammatory diseases, since October 2024, Vor Biopharma Inc. (NASDAQ: VOR), a cell therapies company, since July 2020, and Blueprint Medicines Corporation (NASDAQ: BPMC), a global precision therapy company, since December 2021. Previously, Ms. Beckman served on the board of directors of Translate Bio, Inc., a clinical-stage mRNA therapeutics company, from October 2017 to September 2021, and on the board of 5:01 Acquisition Corp., a special purpose acquisition company, from October 2020 to October 2022. Ms. Beckman holds a B.S. in business administration-accounting from Boston University.

*Adam Crystal, M.D., Ph.D.*, has served as our President of Research and Development since February 2023. Prior to joining Tango, Dr. Crystal served as Chief Medical Officer of C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, from February 2019 to February 2023. From May 2014 to February 2019, Dr. Crystal was a Clinical Program Leader, Senior Director, at Novartis Institutes for BioMedical Research. Dr. Crystal has served as a medical oncologist at Massachusetts General Hospital, where he studied resistance mechanisms to targeted therapies. Dr. Crystal trained at Massachusetts General Hospital in internal medicine and then completed fellowship training in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute in 2013. Dr. Crystal holds an M.D. and a Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine.

*Douglas Barry* has served as our Chief Legal Officer since January 2024 and as Chief Compliance Officer and Corporate Secretary since August 2021. From August 2021 to January 2024, Mr. Barry served as our General Counsel. Mr. Barry has been practicing law for over 20 years, and joined Tango from Alexion Pharmaceuticals, Inc., a biopharmaceutical company that develops and commercializes therapies that serve patients affected by certain rare diseases, where he served as Vice President of Corporate Law from May 2018 to July 2021. Prior to Alexion, he was Associate General Counsel at Alere Inc., a manufacturer and seller of point-of-care diagnostic equipment, from 2015 to 2018 (Alere was acquired by Abbott Laboratories in 2018). Earlier in his career, Mr. Barry spent 10 years as an attorney in the corporate department at Wilmer Cutler Pickering Hale and Dorr LLP. Mr. Barry has a B.A. degree in Political Science from Hobart College, a Master's degree from University of Virginia in International Relations and a juris doctor from Northwestern University School of Law.

## COMPENSATION DISCUSSION AND ANALYSIS

This Compensation Discussion and Analysis, or CD&A, describes the Company's executive compensation program as it relates to the following named executive officers, or NEOs, for 2024:

- Barbara Weber, M.D., our President and Chief Executive Officer;
- Daniella Beckman, our Chief Financial Officer;
- Adam Crystal, M.D., Ph.D., our President of Research and Development; and
- Douglas Barry, our Chief Legal Officer, Chief Compliance Officer and Corporate Secretary

Because we only had four executive officers, as defined under Exchange Act Rule 3b-7, for the year ended December 31, 2024, we only have four named executive officers for the same time period.

## Executive Summary

### Our Company

We are a clinical-stage biotechnology company focused on discovering the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We are focused on using the concept of synthetic lethality—a mechanism describing pairs of genes in which one is inactivated by a genetic alteration and the other is inhibited pharmacologically—to target tumor suppressor gene loss. Our lead programs are PRMT5 inhibitors that utilize the synthetic lethal concept in cancer cells with a homozygous deletion of methylthioadenosine phosphorylase, or MTAP. In 2024 (and early 2025), we made significant progress across our clinical programs and continued to grow our development organization. We achieved a number of significant milestones in 2024, including the following, toward our corporate goals described below in this CD&A section.

### Target and Drug Discovery:

- We achieved the number of validated targets identified by the board of directors and performed the requisite ligandability assessments, all of which increased the possibility of introducing new novel targets for development by the drug discovery team.
- We made meaningful progress towards selection of a potential new drug development candidate.

### Clinical Development:

- In November 2024, we reported positive early data from the ongoing Phase 1/2 clinical trial of TNG462, our lead PRMT5 inhibitor, demonstrating durable clinical activity across multiple cancer types with a strong safety and tolerability profile. We have initiated a robust clinical development program for TNG462.
- In November 2024, we also announced data from the Phase 1/2 clinical trial of TNG908, our first brain-penetrant PRMT5 inhibitor. TNG908 demonstrated clinical activity and was well-tolerated in non-CNS solid tumors. However, TNG908 did not meet the pharmacokinetic exposure threshold for clinical efficacy in glioblastoma and, therefore, we decided to discontinue further development in TNG908 to focus our resources on TNG462 and TNG456.
- In January 2025, the FDA cleared the IND application for TNG456, our next-generation, brain-penetrant PRMT5 inhibitor.
- TNG260, our first-in-class CoREST inhibitor, has demonstrated a favorable safety, tolerability, and pharmacokinetic profile in dose escalation, and we have established clinical proof-of-mechanism based on pharmacodynamic data from on-treatment patient biopsies. We are now enrolling lung cancer patients in the dose expansion portion of our Phase 1 study.

### Corporate Strategy:

- Our collaboration with Gilead Sciences, Inc., or Gilead, continued to progress, as Gilead licensed a drug discovery program for \$12 million in June 2024.
- We maintained our visibility in the scientific and investment communities by submitting more manuscripts than the target number identified by the board of directors and presenting at more scientific and investor conferences than the target number identified by the board of directors.

### People:

- We continued to build a world-class research and development organization by bringing on several key hires, including our Chief Human Resources Officer, Julie Carretero, and multiple key clinical development hires that position the organization to make the anticipated transition into pivotal trials for TNG462 in 2026.
- Our employee turnover rate remained well below market standards and the metric established by our board of directors for 2024.

### Compensation Elements

Our compensation committee seeks to ensure that our compensation program is aligned with the interest of our stockholders and our overall corporate goals. We strive to achieve this by offering a mix of fixed and performance-based compensation, including base salary,

performance-based cash bonus, and long-term equity incentive awards. As described more fully below, key elements of our compensation include:

Compensation Element	Purpose	Features
Base salary	To attract, motivate and retain individuals with superior executive talent.	Fixed component of compensation to provide financial stability, reflecting an individual's skill sets, experience, roles and responsibilities.
Annual performance-based cash bonus	To motivate and reward employees for achieving annual, short-term performance goals linked to the Company's growth and success which are intended to help drive the enhancement of stockholder value, as well as to facilitate executive retention.	Variable component of pay based on annual quantitative and qualitative achievement of pre-determined corporate performance goals. and, in the case of NEOs other than our CEO, the achievement of pre-determined individual performance goals
Equity incentive compensation	To align the interests of our NEOs with those of our stockholders through long-term incentives linked to the Company's stock price performance and to retain and motivate NEOs.	Long-term compensation in the form of stock options and RSUs, which we believe aligns executive and stockholder interest and provides incentives for employee retention.

### Compensation Objectives and Philosophy

Our compensation philosophy is designed to support our goal of building a world-class research and development organization with deep experience and understanding in synthetic lethality in order to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. We have assembled a team of highly experienced senior leaders and oncology drug developers who combine a flexible and adaptive approach to drug development that follows cutting-edge science with the proven expertise of large pharmaceutical company drug discovery and development. The management team and the employees at Tango are what, we believe, will be the ultimate differentiator that sets us apart from the competition as we move our products toward the market.

In 2024, attracting, motivating, and retaining executives and employees that position Tango to meet our corporate objectives, particularly in clinical development and advancing promising drugs towards the clinic, was of increasing importance as we continued to grow the size of our employee base, our operations became more sophisticated and our clinical programs advanced. We believe the work accomplished in 2024 positions us to, among other advancements, provide a clinical data update from our lead PRMT5 inhibitor, TNG462, in 2025, with the goal of moving TNG462 into pivotal trials in 2026. By building a talented and motivated organization around extraordinary leaders, we believe we can advance our product candidates closer to regulatory approval, grow our pipeline and, ultimately, drive long-term and sustainable stockholder value creation. Tango's compensation programs are designed by our compensation committee and our board of directors around the following imperatives:

- **Attract, Retain and Incentivize:** We are committed to (i) attracting, motivating, and retaining industry-leading talented individuals and (ii) designing our compensation programs to incentivize our employees to achieve rigorous corporate and individual objectives that are important to our long-term business and success.
- **Performance-based compensation pay-outs:** Rewarding performance is the keystone of our total compensation program. In our annual bonus program, performance is measured by research and development advances, operational and strategic metrics and, for executive officers other than our CEO, individual contributions. The amount actually earned is scaled with the achievement of these performance metrics.
- **Compensation structure competitive with peers:** We believe that compensation paid by our peer companies matters when we determine overall compensation. We evaluate the practices of our peers to validate that we are competitive with other companies with whom we compete for talent to ensure we are able to attract and retain superior executive talent.
- **Balanced combination of compensation components:** We strive for an appropriate balance between cash and equity incentives. We believe that annual cash incentives motivate individuals to successfully execute on short-term financial and strategic objectives, while equity incentives focus executives on the long-term success of the organization and align the interests of our executives with those of our stockholders.

To date, the compensation of our named executive officers has primarily consisted of a combination of base salary, annual cash bonuses and long-term incentive compensation (in the form of stock options and restricted stock units, or RSUs). All full-time employees, including our named executive officers, are eligible to participate in our retirement and health and welfare benefit plans.

We evaluate our compensation values and philosophy, as well as our compensation plans and arrangements, as circumstances merit. We review executive compensation annually with input from an independent compensation consultant. As part of this review process, the board of directors and the compensation committee apply our values and philosophy, while considering the compensation levels needed to ensure our executive compensation program remains competitive with our peers. In connection with our executive compensation program, we also review whether we are meeting our retention objectives and the potential cost of replacing a key employee.

### **Compensation Governance Practices**

The board of directors and compensation committee recognize that implementing best practices with respect to compensation is important to achieving the goals of operating ethically, transparently and with the aim of achieving long-term stockholder value. Therefore, the following are important aspects of our compensation processes, decisions and programs:

- **Independent Compensation Committee.** Our compensation committee consists solely of independent directors and they meet in executive session as needed and as required by the committee charter.
- **Independent Compensation Advisor.** Our compensation committee engages Pearl Meyer & Partners, LLC, or Pearl Meyer, its own independent compensation advisor, to provide information on compensation developments and trends, peer group analysis related to annual executive compensation decisions and other advice on executive compensation.
- **Pay-for-Performance Guides the Compensation Philosophy.** A significant portion of executive officer compensation is linked to corporate performance and executive compensation includes a significant long-term equity component, thereby making a substantial portion of each executive officer's total compensation at risk and dependent upon our performance and stock price. This incentive structure motivates our executives to take actions that are designed to improve overall Company value and thereby act in the best interests of our stockholders.
- **No Single Trigger Payments on Change in Control.** Change in control payments to our executive officers occur only upon a qualifying termination of employment within a set period of time, not automatically upon a change in control.
- **No Tax Gross-Ups.** We do not provide for tax gross-ups on equity awards or "golden parachute" payments.
- **Compensation Clawback.** The compensation committee has adopted a compensation recovery policy, in compliance with the SEC and Nasdaq listing rules, that requires that, in the event we restate our financial statements due to material noncompliance with any financial reporting requirement, we will recover any incentive-based compensation received by any current or former executive officer in the three years prior to the date that we are required to restate our financial statements that was in excess of the amount that would have been received based on the restated financial statements.

### **Compensation Decision-Making Process**

#### *Role of Board and Compensation Committee*

Our compensation committee oversees the design and implementation of our compensation program for our NEOs and other senior leaders and is primarily responsible for determining the compensation for all of our executive officers and senior leaders. Our compensation committee reviews and discusses management's proposed compensation with our Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, taking into account the factors noted above, the compensation committee then sets the compensation for each executive officer other than the Chief Executive Officer and recommends the compensation for the Chief Executive Officer to our board of directors for approval. Our board of directors discusses the compensation committee's recommendation and ultimately approves the compensation of our Chief Executive Officer without the Chief Executive Officer present.

#### *Role of Compensation Consultant*

Our compensation committee has the authority to engage the services of a consulting firm or other outside advisors to assist it in designing our executive compensation programs and in making compensation decisions. During 2024, the compensation committee continued to retain the services of Pearl Meyer as its external compensation consultant. Pearl Meyer advises on executive compensation matters, including our overall compensation program design and collection of market data to inform our compensation programs for our

executive officers and members of our board of directors. It also reviews executives' contract terms to confirm that such terms are consistent with market information and identifies new trends and developments in executive compensation that the compensation committee should be aware of as it reviews compensation matters. Pearl Meyer reports directly to our compensation committee. As part of the annual compensation review process, our compensation committee assessed Pearl Meyer's independence for 2024 (consistent with Nasdaq listing standards) and concluded that the engagement of such consultant did not raise any conflicts of interest.

### *Peer Group Companies*

To evaluate the total compensation of our NEOs, our compensation committee, with guidance from Pearl Meyer, establishes a peer group of publicly traded biotechnology companies based on the following criteria:

<b>Factor Considered</b>	<b>What We Look For</b>
Industry	Biotechnology or Pharmaceuticals
Number of Employees	75 - 300 employees
Commercial Stage	Pre-commercial clinical stage companies
Market Capitalization	\$300 million - \$3 billion trailing market capitalization
Operating Expense	\$75-300 million operating expense
Therapeutic Area	Oncology
Geography	United States-based
Labor Market Competitor	Companies that we compete with for executive talent

While it is unlikely for all companies to align on all of the factors listed above, we look for the majority of companies to meet all of the factors. Based on these criteria, our peer group for 2024 compensation setting, as approved by our compensation committee, consisted of the following companies:

Ambrx Biopharma Inc.	Inhibrx, Inc.	Nurix Therapeutics, Inc.	Replimune Group, Inc.
Bicycle Therapeutics plc	iTeos Therapeutics, Inc.	Pliant Therapeutics, Inc.	Revolution Medicines, Inc.
Celldex Therapeutics, Inc.	Keros Therapeutics, Inc.	PMV Pharmaceuticals, Inc.	Syndax Pharmaceuticals, Inc.
Dyne Therapeutics, Inc.	Kymera Therapeutics, Inc.	Relay Therapeutics, Inc.	Zentalis Pharmaceuticals, Inc.
Foghorn Therapeutics, Inc.	Merus N.V.	Repare Therapeutics, Inc.	

Our compensation committee reviews our peer group at least annually and updates the peer group as needed. Additionally, due to the nature of our business, we may also compete with larger pharmaceutical companies and prestigious academic and non-profit organizations for executive talent. Our compensation committee believes the compensation practices of our peer group provide us with appropriate benchmarks for evaluating the compensation of our named executive officers.

In addition to the peer group, the compensation committee also reviews industry and size specific compensation survey data to understand the competitiveness for certain of our named executive officer compensation opportunities. This information is intended to generally reflect the profile of the companies in our peer group, and is used when the peer group results for a certain role, or set of roles, do not contain a sufficient enough sample to make appropriate comparisons.

### **Elements of Compensation**

As noted above, the primary elements of our executive compensation program are base salary, annual performance-based cash bonuses, and equity incentive awards. In setting executive base salaries and target cash bonuses and granting equity incentive awards, the compensation committee considered compensation for comparable positions in the market, historical compensation level of our executives, individual performance as compared to our expectations and objectives, our desire to motivate employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to value creation for our Company.

When setting NEO compensation, the compensation committee targets a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, target cash bonus and long-term incentives. While the benchmark data informs the compensation committee's executive compensation decision-making, it does not set compensation at a given percentile relative to the peer group or market data, as the compensation committee recognizes that there are individual factors, such as experience, contribution, increased responsibilities, among other factors, that are also important in setting compensation.

### **Base Salaries**

The annual base salaries of our named executive officers are determined, approved and reviewed periodically by our compensation committee (and our board of directors for the Chief Executive Officer) in order to compensate our named executive officers for their performance of duties to our Company. Annual base salaries are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent. The table below sets forth the named executive officers' base salaries for 2023 and 2024:

Name	2023 Base Salary (\$)	2024 Base Salary (\$)
Barbara Weber, M.D.	627,000	660,000
Daniella Beckman	442,100	486,314
Adam Crystal, M.D., Ph.D.	550,000	569,250
Douglas Barry (1)	435,942	451,200

(1) Mr. Barry was not a named executive officer until 2024.

The compensation committee, in setting base salary compensation for the named executive officers (and all Company employees) for 2024, implemented a minimum increase to base salaries of 3.5% which, based on regional market data, reflect an increase in the cost-of-living. This was done to ensure that employees had salaries that allowed them to maintain their purchasing power and to remain competitive with the companies with which we compete for talent. Base salary increases for 2024 were effective as of January 1, 2024.

Dr. Weber's base salary was increased in 2024 by an additional 5% (for a total increase of 8.5%). The compensation committee and the board of directors noted that the CEO's base salary was below the 50th percentile base salary for chief executive officers in the Company's peer group. The increase in Dr. Weber's base salary aligned her base salary with the 50th percentile chief executive officer base salary at our peer group companies (the compensation committee has generally targeted the CEO's base salary to be at the 50th percentile for all other peer group chief executive officer's base salaries). As noted above, the compensation committee compensation philosophy is to pay the executive officers a base salary that is competitive with the companies that we compete with for talent, and this increase was designed to, among other things, meet that compensation objective.

Ms. Beckman's base salary was increased in 2024 by an additional 6.5% (for a total increase of 10%) to reflect the increase in the cost-of-living and to bring Ms. Beckman's base salary into better alignment with the peer group. This base salary was consistent with the 50th percentile of the peer group and other market data.

Dr. Crystal's base salary was increased in 2024 by 3.5% to reflect the increase in the cost-of-living. This base salary was consistent with the 50th percentile of the peer group and other market data.

Mr. Barry's base salary was increased in 2024 by 3.5% to reflect the increase in the cost-of-living. This base salary was consistent with the 50th percentile of the peer group and other market data.

#### ***Non-Equity Incentive Plan Compensation***

Our annual cash bonus program is intended to recognize and reward employees for achieving established objectives that are linked to the Company's growth and success, with the goal of incentivizing our executives to take steps to meet our short-term financial and strategic objectives, thereby establishing the foundation for increasing the Company's intrinsic long-term value. The program rewards performance based on corporate and individual accomplishments (other than with respect to the CEO, whose annual cash bonus is determined solely based on corporate accomplishments). The compensation committee and the board endeavor to deliver a meaningful portion of total target cash compensation in the form of performance-based annual cash incentives. The board and the compensation committee believe that doing so is critical because the opportunity for a meaningful cash award will, together with strong management and accountability, drive executives to individually and collectively achieve and exceed our annual objectives. This approach supports the compensation committee's goal of linking a substantial portion of overall compensation to Company and the individual performance.

The board of directors established bonus metrics that the compensation committee utilized in connection with the 2024 annual cash bonus program. The board of directors sets goals at the start of each performance year, in consultation with the compensation committee, and then the board tracks actual performance against these goals at each board meeting, with a final assessment occurring at the end of the annual performance year. Our Company performance goals are consistent throughout the organization to ensure there is full alignment and clarity on the critical goals for Tango.

The 2024 annual cash bonus program provided for formula-based incentive payments based upon the achievement of certain corporate and individual performance goals and objectives approved by our compensation committee and board of directors. These targets were

established in early 2024 and communicated to the executives (and remained unchanged during the year with the exception of the advancement of TNG348). Bonuses are targeted at a percentage of the executive officer's base salary, and, to the extent earned, are paid out in the first quarter of the following year. In 2024, the board of directors and the compensation committee determined that it would maintain the bonus target for Ms. Beckman and Dr. Crystal to be consistent with their respective bonus targets in 2023, but increased the target bonuses, as a percentage of base salary, for Dr. Weber and Mr. Barry to better align with peer group data.

The table below sets forth the named executive officers' target annual cash bonus percentages for 2023 and 2024:

Name	2023 Bonus Target (%)	2024 Bonus Target (%)
Barbara Weber, M.D.	55 %	60 %
Daniella Beckman	40 %	40 %
Adam Crystal, M.D., Ph.D.	45 %	45 %
Douglas Barry (1)	35 %	40 %

(1) Mr. Barry was not a named executive officer until 2024.

The corporate component of the 2024 annual cash bonus program consisted of the five separate metrics described below that were weighted as follows:

- **Target Discovery** - weighted 10%. This target was designed to encourage our employees to identify validated novel targets and perform ligandability assessments to establish an enhanced and sustainable product pipeline that is designed to serve as the foundation for future clinical stage assets and growth opportunities for the Company.
- **Drug Discovery** - weighted 10%. This target was established to incentivize our employees to continue to advance our identified programs into advanced drug discovery phases.
- **Clinical Development** - weighted 50%. Given the importance of the clinical trial program to the Company's overall success and its long-term intrinsic value, drug development was the factor with the highest weighting as determined by the board of directors. This target was designed to meet our goals of: submitting an IND for TNG456, progressing on-going TNG462 clinical trials into dose expansion and establishing proof-of-concept for TNG260. The board of directors had also established an objective relating to TNG348, but the program was discontinued due to toxicity observed in the initial study cohorts.
- **Corporate Strategy** - weighted 20%. This target was established to incentivize our employees to continue to generate scientific publications and disclosures that highlight the strength of our science, our discovery platform and our programs, as well as to meet budgetary and other important cash-based goals that are designed to allow for continued development of our product pipeline and the advance of clinical development programs in the future.
- **People** - weighted 10%. This target was designed to reward results with respect to: (i) engagement survey results conducted with our associates, (ii) building out critical functions of our organization as we advanced our clinical trials and (iii) limiting employee turnover in a competitive environment for talent.

In consultation with the board of directors, the compensation committee determined that the overall achievement of the corporate performance metrics for the 2024 annual cash bonus program was 113% of target for all employees, including the named executive officers. The following provides a description of the factors that the board of directors and the compensation committee considered in determining achievement of the metrics and the approved level of achievement:

- **Target Discovery** - the goal was achieved at 110% of the target due to meeting the number of validated targets established by the board of directors and performing the requisite ligandability assessments, all of which increased the potential to introduce new novel targets for development by the drug discovery team.
- **Drug Discovery** - the goal was achieved at 90% of the target as a result of meaningful progress toward selection of a potential new development candidate, but there was slower progress on two targets.
- **Clinical Development** - the goal was achieved at 125% of the target due to having established proof-of-concept for each of TNG908, TNG462 and TNG260 during the year, completing the initial data release on TNG908 and TNG462, advancing substantial work on the TNG456 IND and the significant achievement of operating four clinical trials during the year and all being conducted either on schedule or ahead of schedule.
- **Corporate Strategy**- the goal was achieved at 90% of the target. While the scientific publications and presentations surpassed the existing objectives, goals with respect to certain financial metrics were below the established targets.

- **People** - the goal was achieved at 120% of the target due to the growth in the Company's headcount in certain important functional areas, including the additions of Ms. Carretero as Chief Human Resources Officer and key clinical development competencies that supported the conduct and advancement of our clinical trials. In addition, our employee turnover rate remained well below market standards and the metric established by the board of directors.

As a result of this performance, which exceeded many of the objective goals set for 2024, the bonus payout based on the achievement of such objectives was approved at 113% of target.

The following table reflects the target bonus as a percentage of base salary, the cash bonus payment at target and the actual bonus payout based on the success Tango achieved in 2024.

Name	2024 Bonus Target (%)	2024 Bonus Target (\$)	Actual 2024 Bonus (\$)
Barbara Weber, M.D.	60 %	396,000	447,477
Daniella Beckman	40 %	194,526	213,492
Adam Crystal, M.D., Ph.D.	45 %	256,163	297,149
Douglas Barry	40 %	180,480	204,845

All final bonus payments to our named executive officers are determined by our compensation committee (with the exception of the CEO, whose final bonus payment is determined by the board of directors), which, in each case, retains full discretion to adjust individual actual bonus awards based on the achievement of corporate and individual performance objectives, and may also adjust bonus awards based on other factors in their discretion. The compensation committee allocated 75% of the aggregate 2024 bonus payment to the corporate performance metrics and 25% to individual performance for named executive officers other than the CEO, whose final bonus payment is determined solely based on corporate performance and does not have an individual performance allocation. The board of directors determined that since Dr. Weber is responsible for overall corporate performance, the full amount of her cash bonus payment should be determined by reference to corporate performance relative to the metrics set by the board of directors, and not take into account any individual performance metrics. Individual performance objectives used for the other named executive officers are generally related to such named executive officer's performance in his or her area of responsibility and his or her contributions to Tango, as well as embodying and living the Company's core cultural values (which includes team building and contributions, investing time in developing leaders and modeling diligence and professionalism in interactions with colleagues). The individual objectives assigned in 2024 to our named executive officers other than our CEO were as follows:

- Daniella Beckman: Ms. Beckman was assigned objectives related to: (i) expanding corporate presence and influence, both externally and internally; and (ii) ensuring the continued evolution and excellence of the finance, business development, communications, information systems and facilities functional capabilities and processes to meet the needs of the company. For 2024, the compensation committee determined that Ms. Beckman achieved the combined performance metrics (*i.e.*, corporate and individual metrics, including individual performance related to the Company's core values, together, at 110%).
- Adam Crystal, M.D., Ph.D.: Dr. Crystal was assigned objectives related to (i) the continued advancement of the research and development pipeline, and (2) driving our clinical organization to enroll patients in clinical trials and execute on preparation for multiple monotherapy and combination trials in 2025 and 2026. For 2024, the compensation committee determined that Dr. Crystal achieved the combined performance factors at 116%.
- Douglas Barry: Mr. Barry was assigned objectives relating to (i) establishing efficient contracting procedures to support the organization and (ii) developing standard operating procedures on certain legal and compliance processes. For 2024, the compensation committee determined that Mr. Barry achieved the combined performance factors at 114%.

### Equity Incentive Compensation

Our equity incentive awards granted to our named executive officers are designed to align their interests with those of our stockholders, and to retain and motivate our NEOs.

We have historically used stock options as our primary form of long-term incentive compensation awards to our executive officers because stock options allow our executive officers to profit from this form of equity compensation only if our stock price increases relative to the stock option's exercise price, which exercise price is set at the fair market value of our common shares on the date of grant. In 2023 and 2024, the compensation committee included restricted stock units, or RSUs, as a component of the long-term equity incentive package, in addition to stock options. The compensation committee determined that RSUs would be a valuable component of the overall compensation package for a number of reasons, including: (i) the use of RSUs as a part of equity compensation was being adopted by peer companies, and the inclusion of such awards allows for the attraction and retention of key talent as competition for talent increases, (ii) RSUs can provide value to executives and employees in a volatile market, and (iii) we can grant fewer RSUs than shares underlying

options at an equivalent grant date fair value, which minimizes the dilution to our existing stockholders. For 2023 and 2024, the compensation committee determined to grant one RSU for every two shares of stock subject to a stock option award (a 2:1 ratio).

Along with the 2024 cash bonus program, stock options and RSUs are a critical component of the variable portion of overall compensation that is designed to reward executive officer performance. Equity awards encourage our executives to focus on those corporate actions that drive increases in long-term value as reflected in our stock price. Further, the four-year vesting schedule encourages executives to remain employed by the Company for an extended period. As noted above, we believe RSUs, which accounted for a minority of the total annual equity package granted to each of our executives and employees in 2024, incentivize a focus on long-term value and stockholder interests even when market conditions may cause stock prices to decrease and further our objectives of retaining and motivating employees in a competitive market.

We grant equity awards at such times as our board of directors or compensation committee determines appropriate. The Company's equity incentive program is reviewed on an annual basis by our compensation committee (usually in November or December of the year preceding the year in which grants are made) to analyze and confirm that the equity component of the compensation program is achieving its objectives to reward long-term performance and motivate and retain our NEOs. Our compensation committee reviews and determines the appropriate equity awards to be used that align with our business needs, our pay-for-performance philosophy and the practices of our peer group. The actual award or awards granted to each executive officer differ based on criticality and impact of the job on the Company, individual performance results, potential future expected contributions, skills, market competitiveness and other factors that the compensation committee determines necessary in order to advance the goals of our compensation philosophy.

Our executives generally are awarded an initial equity grant in connection with their commencement of employment with us. Additional grants may be made periodically in order to specifically incentivize executives with respect to achieving corporate goals or to reward certain performance. Our stock options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in 36 equal monthly installments over the following three years, subject to the holder's continued service relationship with us. All options are granted with an exercise price that is no less than the fair market value of our common stock on the date of such grant of such award. Our RSUs typically vest in three equal annual installments, subject to the holder's continued service relationship with the Company. From time to time, the board of directors or compensation committee may also use alternative vesting schedules as it determines are appropriate to motivate particular employees.

The table below sets forth the equity awards granted to our named executive officers in 2024:

Name	Number of Shares Underlying Stock Options Granted in 2024	Number of Shares Underlying Stock Awards Granted in 2024
Barbara Weber, M.D.	523,012	87,168
Daniella Beckman	236,475	39,413
Adam Crystal, M.D., Ph.D.	279,593	46,599
Douglas Barry	137,156	22,859

## **Other Elements of Compensation; Perquisites**

### ***Health and Welfare Plans***

During their employment, our named executive officers are eligible to participate in our employee benefit plans and programs, including medical and dental benefits, life insurance and disability benefits, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans.

### ***Retirement Plan***

We maintain a 401(k) retirement savings plan for our employees, including our NEOs, who satisfy certain eligibility requirements. The savings plan is intended to qualify for favorable tax treatment under Section 401(a) of the Internal Revenue Code of 1986, as amended, or the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. In 2022, our compensation committee authorized the Company to begin matching employee contributions up to a maximum of 100% of the first 2% of eligible compensation and 50% of the next 4% of eligible compensation during each pay period, subject to statutory limits. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees.

## Compensation Risk Assessment

We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on the Company.

## Compensation Recovery Policy

In accordance with the requirements of the SEC and Nasdaq listing rules, the compensation committee has adopted a compensation recovery policy (effective as of October 2, 2023). The compensation recovery policy provides that in the event we are required to prepare a restatement of our financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover (subject to certain limited exceptions set forth in the compensation recovery policy and permitted by Nasdaq listing rules) any incentive-based compensation that was based upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officer would have received based on the restated financial statements. The compensation recovery policy is filed as Exhibit 97.1 to the 2024 Annual Report.

## Equity Award Grant Practices

The Company has an Equity Grant Award Policy to standardize the process of granting equity in accordance with applicable legal and regulatory requirements, and to enhance its internal controls. Under this policy, equity awards to the Company's employees, including NEOs, are typically approved by the board of directors, the compensation committee, or its/their delegate and granted on an annual basis on a predetermined date in the month of February. Equity grants to certain newly hired employees or promoted individuals, including executive officers, are made on the first trading day of each month following the later of (i) the date on which such individual's employment begins or promotion occurs or (ii) the date on which such grant is approved by the board of directors, the compensation committee, or its/there delegate(s). It is the Company's policy to not purposely accelerate or delay the release of material nonpublic information in consideration of a pending equity award in order to allow the grantee to benefit from a more favorable stock price.

As required pursuant to Item 402(x) of Regulations S-K, the following table provides information regarding option awards granted to our named executive officers in the fiscal year ended December 31, 2024, during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing of such report with the Securities and Exchange Commission.

Name	Grant Date	Number of Securities Underlying the Award	Exercise Price of the Award (\$/Share)	Grant Date Fair Value of the Award	Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information
Barbara Weber, M.D.	2/1/2024	523,012	12.28	8.31	0.01 %
Daniella Beckman	2/1/2024	236,475	12.28	8.31	0.01 %
Adam Crystal, M.D., Ph.D.	2/1/2024	279,593	12.28	8.31	0.01 %
Douglas Barry	2/1/2024	137,156	12.28	8.31	0.01 %

## Tax Deductibility

Under Section 162(m) of the Internal Revenue Code, publicly held corporations generally may not deduct compensation in excess of \$1 million paid to certain executive officers, subject to limited transition relief for certain arrangements in place as of November 2, 2017. The compensation committee believes that its primary responsibility is to provide a compensation program that attracts, engages, retains and rewards the executive officers necessary for the Company's success, as described above. As a result, while the compensation committee considers tax deductibility as one factor in determining executive compensation, we currently and may in the future pay compensation that is not fully deductible, in whole or in part, under Section 162(m) in order to ensure competitive levels of total compensation for our executive officers and when we otherwise view such compensation as consistent with our compensation policies.

## Accounting for Stock-Based Compensation

We follow Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC Topic 718, for our stock-based compensation awards to employees and directors. ASC Topic 718 requires companies to measure the compensation expense for all share-based awards, including stock options and RSUs, based on the grant date “fair value” of these awards. This calculation is performed for accounting purposes and reported in the compensation tables below, even though our executive officers or directors may never realize any value from their awards. ASC Topic 718 also requires companies to recognize the compensation cost of their stock-based compensation awards in their statements of operations over the period that an employee or director is required to render service in exchange for the option or other award. The compensation committee considers the impact of ASC Topic 718 when making stock-based compensation awards.

### Summary Compensation Table

Name and Principal Position	Year	Salary \$(1)	Bonus \$(3)	Stock Awards \$(2)	Option Awards \$(2)	Non-Equity Incentive Plan Compensation \$(3)	All Other Compensation \$(5)	Total \$(5)
Barbara Weber, M.D.(4) <i>President, Chief Executive Officer and Director</i>	2024	659,996	—	1,070,423	4,345,288	447,477	18,016 (5)	6,541,200
	2023	625,997	—	465,634	1,885,613	396,576	17,238	3,391,059
	2022	575,000	—	—	3,740,625	363,688	2,474	4,681,787
Daniella Beckman <i>Chief Financial Officer</i>	2024	486,314	—	483,992	1,964,682	213,492	17,810 (6)	3,166,290
	2023	441,777	—	170,778	691,570	209,999	8,620	1,522,744
	2022	425,100	—	—	897,750	191,614	2,415	1,516,879
Adam Crystal, M.D., Ph.D.(7) <i>President of Research and Development</i>	2024	569,250	—	572,236	2,322,915	297,149	15,768 (8)	3,777,318
	2023	454,808	275,000	422,500	1,710,930	242,787	4,621	3,110,646
	2022	451,200	—	280,709	1,139,519	204,845	18,177 (10)	2,094,450

- (1) Salary amount represents actual amounts paid for the years noted. See the CD&A above for additional information.
- (2) In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards or RSU awards computed in accordance with ASC Topic 718, disregarding the effect of estimated forfeitures related to service-based vesting. See Note 2 and Note 11 to our audited financial statements contained in our Annual Report on Form 10-K filed with the SEC on February 27, 2025 for a discussion of assumptions made in determining the aggregate grant date fair value of stock option and RSU awards. These amounts do not reflect the actual economic value that may be realized by the named executive officer upon the vesting or exercise of the stock options or the sale of the common stock underlying such stock options or the vesting of RSUs and the sale of the shares received upon the vesting of the RSUs.
- (3) Reflects performance-based annual cash bonuses awarded to our named executive officers. See “CD&A — Non-Equity Incentive Plan Compensation” above for a description of the material terms of the program pursuant to which this compensation was earned.
- (4) Dr. Weber also serves as a member of our board of directors but does not receive any additional compensation for her service as a director.
- (5) The amounts reported include \$13,800 of matching contributions made under our 401(k) plan, \$2,170 of commuter benefits and \$1,300 of expenses for phone services that the Company paid for on behalf of Dr. Weber.
- (6) The amounts reported include \$13,800 of matching contributions made under our 401(k) plan, \$2,170 of commuter benefits and \$1,300 of expenses for phone services that the Company paid for on behalf of Ms. Beckman.
- (7) Dr. Crystal’s employment with Tango began on February 27, 2023. His base salary and bonus were prorated to reflect his partial year of employment from February 27, 2023 through December 31, 2023.
- (8) The amounts reported include \$12,174 of matching contributions made under our 401(k) plan, \$2,170 of commuter benefits and \$1,300 of expenses for phone services that the Company paid for on behalf of Dr. Crystal.
- (9) Douglas Barry was not a named executive officer until 2024. Prior year compensation is excluded.
- (10) The amounts reported include \$13,800 of matching contributions made under our 401(k) plan, \$2,170 of commuter benefits and \$1,300 of expenses for phone services that the Company paid for on behalf of Mr. Barry.

### Grants of Plan-Based Awards for Fiscal Year 2024

The following table presents information regarding each grant of an award made to our named executives officer during the fiscal year ended December 31, 2024 under any plan, contract, authorization or arrangement pursuant to which cash, securities, similar instruments or other property may be received.

Name	Grant Date	Date of Compensation Committee Approval	Estimated Future Payouts Under Non-Equity Incentive Plan Awards (1) Target (\$)	All other stock awards: Number of shares of stock or units (#) (2)	All other option awards: Number of securities underlying options (#)	Exercise or base price of option awards (\$/Sh)(3)	Grant date fair value of stock and option awards (4)
Barbara Weber, M.D.	2/1/2024	12/10/2023	396,000	87,168	—	—	1,070,423
	2/1/2024	12/10/2023		—	523,012	12.28	4,345,288
Daniella Beckman	2/1/2024	12/10/2023	194,526	39,413	—	—	483,992
	2/1/2024	12/10/2023		—	236,475	12.28	1,964,682
Adam Crystal, M.D., Ph.D.	2/1/2024	12/10/2023	256,163	46,599	—	—	572,236
	2/1/2024	12/10/2023		—	279,593	12.28	2,322,915
Douglas Barry	2/1/2024	12/10/2023	180,480	22,859	—	—	280,709
	2/1/2024	12/10/2023		—	137,156	12.28	1,139,519

- (1) Amounts shown in the “Target (\$)” column reflect the target amounts payable to each named executive officer under our 2024 annual cash bonus plan as described under “*CD&A — Non-Equity Incentive Plan Compensation*” above. Actual payments attributable to performance in 2024 are provided in the “2024 Summary Compensation Table” above. There are no threshold or maximum amounts with respect to these performance-based cash payments.
- (2) The amounts shown represent the number of RSUs granted pursuant to our 2021 Stock Option and Incentive Plan, or the 2021 Plan.
- (3) The exercise price of these stock options is equal to the closing price of our common stock as reported on the Nasdaq Global Select Market on the grant date.
- (4) These amounts represent the aggregate grant date fair value of stock option awards and RSU awards granted to our named executive officers in 2024, computed in accordance with ASC Topic 718, disregarding the effect of estimated forfeitures related to service-based vesting. See Note 2 and Note 11 to our audited financial statements contained in our Annual Report on Form 10-K filed with the SEC on February 27, 2025 for a discussion of assumptions made in determining the aggregate grant date fair value of stock option and RSU awards. These amounts do not reflect the actual economic value that may be realized by the named executive officer upon the vesting or exercise of the stock options or the sale of the common stock underlying such stock options or the vesting of RSUs and the sale of the shares received upon the vesting of the RSUs.

#### Outstanding Equity Awards at 2024 Fiscal Year-End

The following table presents information regarding all outstanding equity awards held by each of our named executive officers as of December 31, 2024.

Name	Grant Date	Vesting Commencement Date	Option Awards				Stock Awards		
			Number of Securities Underlying Unexercised Options (#) Exercisable (1)	Number of Securities Underlying Unexercised Options (#) Unexercisable (1)	Option Exercise Price (\$)(2)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested (\$)(3)	
Barbara Weber, M.D.	1/24/2019	1/1/2019	219,151	— (4)	1.53	1/23/2029	—	—	—
	1/30/2020	1/1/2020	219,150	— (4)	1.65	1/29/2030	—	—	—
	1/28/2021	1/1/2021	1,257,313	26,752 (4)	3.50	1/27/2031	—	—	—
	8/12/2021	8/12/2021	801,170	160,234 (4)	9.56	8/11/2031	—	—	—
	2/1/2022	1/1/2022	455,729	169,271 (4)	9.22	1/31/2032	—	—	—
	3/1/2023	1/1/2023	257,443	279,830 (4)	5.20	2/28/2033	59,697 (7)	184,464	—
	2/1/2024	1/1/2024	—	523,012 (4)	12.2 <sub>8</sub>	1/31/2034	87,168 (8)	269,349	—
	Daniella Beckman	10/18/2019	9/10/2019	165,433	— (5)	1.53	10/17/2029	—	—
	1/30/2020	11/1/2019	55,201	— (5)	1.65	1/29/2030	—	—	—
	10/1/2020	7/1/2020	68,108	— (5)	3.21	9/30/2030	—	—	—
	1/28/2021	1/1/2021	86,314	1,837 (4)	3.50	1/27/2031	—	—	—
	8/12/2021	8/12/2021	317,070	63,415 (4)	9.56	8/11/2031	—	—	—
	2/1/2022	1/1/2022	109,375	40,625 (4)	9.22	1/31/2032	—	—	—
	3/1/2023	1/1/2023	94,419	102,632 (4)	5.20	2/28/2033	21,895 (7)	67,656	—
	2/1/2024	1/1/2024	—	236,475 (4)	12.2 <sub>8</sub>	1/31/2034	39,413 (8)	121,786	—
Adam Crystal, M.D., Ph.D.	3/1/2023 (6)	2/27/2023	223,437	264,063 (4)	5.20	2/28/2033	54,166 (7)	167,373	—
	2/1/2024	1/1/2024	—	279,593 (4)	12.2 <sub>8</sub>	1/31/2034	46,599 (8)	143,991	—
Douglas Barry	8/12/2021	8/12/2021	205,246	41,050 (4)	9.56	8/11/2031	—	—	—
	2/1/2022	1/1/2022	50,677	18,823 (4)	9.22	1/31/2032	—	—	—
	3/1/2023	1/1/2023	68,707	74,684 (4)	5.20	2/28/2033	15,932 (7)	49,230	—
	2/1/2024	1/1/2024	—	137,156 (4)	12.2 <sub>8</sub>	1/31/2034	22,859 (8)	70,634	—

- (1) Each stock option granted prior to the closing of the Business Combination in August 2021 was granted under our 2017 Stock Option and Grant Plan, or the 2017 Plan. Each stock option and RSU award granted after the closing of the Business Combination was granted pursuant to our 2021 Plan, unless otherwise noted.
- (2) All of the option awards listed in the table were granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. For information regarding the valuation of equity awards, see Note 2 and Note 11 to our audited financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on February 27, 2025. The amounts presented do not correspond to the actual value that may be recognized by the named executive officer upon vesting or exercise of the stock options or the sale of the shares of common stock underlying such stock options.
- (3) The market value of the RSU awards is based on the closing price of \$3.09 per share of the Company's common stock on December 31, 2024, the last trading day of the year, as reported on the Nasdaq Global Market.
- (4) These stock options vest as follows: 25% of the shares vest on the first anniversary of the vesting commencement date and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, subject to continued employment with the Company through the applicable vesting date.
- (5) These stock options vested in equal monthly installments over 48 months following the vesting commencement date, subject to continued employment with the Company through the applicable vesting date.
- (6) These stock options and RSUs were granted pursuant to our 2023 Inducement Plan.
- (7) These RSUs vest in equal annual installments over three years on each of February 5, 2024, February 3, 2025 and February 2, 2026, subject to the named executive officer's continued employment with the Company through the applicable vesting date.
- (8) These RSUs vest in equal annual installments over three years on each of February 3, 2025, February 2, 2026 and February 1, 2027, subject to the named executive officer's continued employment with the Company through the applicable vesting date.

#### Option Exercises and Stock Vested in 2024

The following table presents information regarding option exercises and the vesting of RSU awards by each of our named executive officers during the fiscal year ended December 31, 2024.

Name	Option Awards		Stock Awards	
	Number of Shares Acquired on Exercise (#)(1)	Value Realized on Exercise (\$)	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting (\$)(2)
Barbara Weber, M.D.	—	—	29,848	371,906
Daniella Beckman	—	—	10,947	136,400
Adam Crystal, M.D., Ph.D.	—	—	27,084	337,467
Douglas Barry	—	—	7,966	99,256

- (1) There were no option exercises by the named executive officers during the year ended December 31, 2024.
- (2) The value realized upon vesting of RSUs is calculated by multiplying the number of RSUs vested by the closing price market price of a share of our common stock as reported on the Nasdaq Global Select Market on the vest date.

### Equity Compensation Plan Information

The following table sets forth information as of December 31, 2024 regarding shares of common stock that may be issued under our equity compensation plans, consisting of our 2023 Inducement Plan (as described below), our 2021 Plan, our 2021 Employee Stock Purchase Plan, or the ESPP, and our 2017 Plan. As of December 31, 2024, other than the 2023 Inducement Plan, we did not have any non-stockholder approved equity compensation plans. The compensation committee adopted the 2023 Inducement Plan in March 2023, under which we reserved an aggregate of 3,000,000 shares of common stock, to be used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with the Company pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Plan Category	Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights(#)	Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights(\$)(1)	Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column 1)(#)
Equity compensation plans approved by stockholders(2)	19,835,164 (3)	7.51	10,085,905 (4)
Equity compensation plans not approved by security holders	989,192 (5)	5.31	1,975,390 (6)
<b>Total</b>	<b>20,824,356</b>	<b>7.40</b>	<b>12,061,295</b>

- (1) The calculation does not take into account shares of common stock subject to outstanding RSUs, which do not have an associated exercise price.
- (2) The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase each January 1 by 5% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser amount as determined by the administrator of the 2021 Plan. This limit is subject to adjustment in the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split or other similar change in the Company's capitalization. The ESPP provides that the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1 by the least of (i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31, (ii) 949,873 shares of common stock or (iii) such lesser amount as determined by the administrator of the ESPP. This limit is subject to adjustment in the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split or other similar change in the Company's capitalization.
- (3) This number includes 14,441,234 shares of our common stock subject to outstanding options granted under our 2021 Plan, 1,100,219 unvested RSUs under our 2021 Plan, and 4,293,711 shares of our common stock subject to outstanding options granted under our 2017 Plan.
- (4) Includes 7,054,673 shares available for grant under the 2021 Plan, 3,031,232 shares available under the 2021 ESPP and zero shares available for grant under the 2017 Plan.
- (5) Includes 880,078 shares of common stock issuable upon the exercise of outstanding stock options and 109,114 unvested RSUs.
- (6) Includes 1,975,390 shares of common stock available under the 2023 Inducement Plan.

### Executive Compensation Arrangements

Effective upon the closing of the Business Combination in 2021, we entered into employment agreements with Dr. Weber and Ms. Beckman that provide for specified payments and benefits in connection with a termination of employment in certain circumstances. Dr. Crystal and Mr. Barry each entered into an employment agreement in connection with the commencement of their employment in February 2023 and August 2021, respectively. These agreements provide for specified payments and benefits in connection with a

termination of employment in certain circumstances. Our goal in providing these severance and change in control payments and benefits is to offer sufficient cash continuity protection such that the named executive officers will focus their full time and attention on the requirements of the business rather than the potential implications for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the named executive officers, rather than negotiating severance at the time that a named executive officer's employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate because they encourage our named executive officers to stay focused on the business in those circumstances, rather than focusing on the potential implications for them personally. The employment agreements with our named executive officers require the named executive officers to execute a separation agreement containing a general release of claims in favor of us to receive any severance payments and benefits. The material terms of the employment agreements with Dr. Weber, Ms. Beckman, Dr. Crystal, and Mr. Barry are summarized below.

***Barbara Weber, M.D.***

Under Dr. Weber's employment agreement, or the Weber Employment Agreement, Dr. Weber serves as our Chief Executive Officer on an at-will basis. Dr. Weber's annual base salary is subject to periodic review and adjustment by the board of directors, and she is eligible to earn an annual bonus with a target amount expressed as a percentage of her base salary, which target amount is set annually by the board of directors. Dr. Weber is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.

Pursuant to the Weber Employment Agreement, in the event that Dr. Weber's employment is terminated by us without "cause" or Dr. Weber resigns for "good reason" (as each term is defined in the Weber Employment Agreement), subject to her execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive base salary continuation for 12 months following termination, (ii) she will be entitled to receive a prorated portion of her target annual cash incentive compensation for the year of termination, payable over the 12 months following termination, (iii) she will be entitled to receive any earned but unpaid bonus for the prior year, (iv) subject to Dr. Weber's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr. Weber had she remained employed with us until the earliest of (A) 12 months following termination, (B) Dr. Weber's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Dr. Weber's COBRA health continuation period, and (v) she will be entitled to 12 months of acceleration of the unvested portion of all stock options and other stock-based awards subject solely to time-based vesting held by Dr. Weber.

In lieu of the payments and benefits described in the preceding sentence, in the event that Dr. Weber's employment is terminated by us without cause or Dr. Weber resigns for good reason on or within 12 months following a "change in control" (as defined in the Weber Employment Agreement), subject to her execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive a lump sum in cash equal to 18 months of her then-current annual base salary (or Dr. Weber's annual base salary in effect immediately prior to the change in control, if higher), (ii) she will be entitled to receive a lump sum in cash equal to 1.5 times Dr. Weber's target annual cash incentive compensation for the year of termination, (iii) she will be entitled to receive a lump sum in cash equal to a prorated portion of her target annual cash incentive compensation for the year of termination, (iv) she will be entitled to receive any earned but unpaid bonus for the prior year, (v) subject to Dr. Weber's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr. Weber had she remained employed with us until the earliest of (A) 18 months following termination, (B) Dr. Weber's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Dr. Weber's COBRA health continuation period, and (vi) she will be entitled to acceleration of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by her.

***Daniella Beckman***

Under Ms. Beckman's employment agreement, or the Beckman Employment Agreement, Ms. Beckman serves as our Chief Financial Officer on an at-will basis. Ms. Beckman's annual base salary is subject to periodic review and adjustment by the compensation committee, and she is eligible to earn an annual bonus with a target amount expressed as a percentage of her base salary, which target amount is set annually by the compensation committee. Ms. Beckman is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.

Pursuant to the Beckman Employment Agreement, in the event that Ms. Beckman's employment is terminated by us without "cause" or Ms. Beckman resigns for "good reason" (as each term is defined in the Beckman Employment Agreement), subject to her execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive base salary continuation for 12 months following termination, and (ii) subject to Ms. Beckman's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, we will cover the portion of the premium

amount equal to the amount that we would have paid to provide health insurance to Ms. Beckman had she remained employed with us until the earliest of (A) 12 months following termination, (B) Ms. Beckman's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Ms. Beckman's COBRA health continuation period.

In lieu of the payments and benefits described in the preceding sentence, in the event that Ms. Beckman's employment is terminated by us without cause or Ms. Beckman resigns for good reason on or within 12 months following a "change in control" (as defined in the Beckman Employment Agreement), subject to her execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive a lump sum in cash equal to 12 months of her then-current annual base salary (or Ms. Beckman's annual base salary in effect immediately prior to the change in control, if higher), (ii) she will be entitled to receive a lump sum in cash equal to her target annual cash incentive compensation for the year of termination, (iii) subject to Ms. Beckman's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Ms. Beckman had she remained employed with us until the earliest of (A) 12 months following termination, (B) Ms. Beckman's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Ms. Beckman's COBRA health continuation period, and (iv) she will be entitled to acceleration of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by her.

***Adam Crystal, M.D., Ph.D.***

Under Dr. Crystal's employment agreement, or the Crystal Employment Agreement, Dr. Crystal's annual base salary is subject to periodic review and adjustment by the compensation committee, and he is eligible to earn an annual bonus with a target amount expressed as a percentage of his base salary, which target amount is set annually by the compensation committee. Dr. Crystal also received a one-time sign-on bonus of \$275,000, which was subject to repayment by Dr. Crystal if he had voluntarily left Tango prior to February 27, 2024. Dr. Crystal is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.

Pursuant to the Crystal Employment Agreement, in the event that Dr. Crystal's employment is terminated by us without "cause" or Dr. Crystal resigns for "good reason" (as each term is defined in the Crystal Employment Agreement), subject to his execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) he will be entitled to receive base salary continuation for twelve (12) months following termination and his unpaid cash bonus payments for the preceding year, (ii) he will be entitled to receive any unpaid cash bonus for the preceding fiscal year and a pro-rata bonus for the portion of the year through the date of termination, and (iii) subject to Dr. Crystal's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, the Company will cover the portion of the premium amount equal to the amount that it would have paid to provide health insurance to Dr. Crystal had he remained employed with the Company until the earliest of (A) 12 months following termination, (B) Dr. Crystal's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Dr. Crystal's COBRA health continuation period.

In lieu of the payments and benefits described in the preceding sentence, in the event that Dr. Crystal's employment is terminated by the Company without cause or Dr. Crystal resigns for good reason on or within 12 months following a "change in control" (as defined in the Crystal Employment Agreement), subject to his execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) he will be entitled to receive a lump sum in cash equal to 12 months of his then-current annual base salary (or Dr. Crystal's base salary in effect immediately prior to a change in control, if higher), (ii) he will be entitled to receive a lump sum in cash equal to his target annual cash incentive compensation for the year of termination, (iii) he will be entitled to receive any unpaid cash bonus for the preceding fiscal year and pro-rata bonus for the portion of the year through the date of termination, (iv) subject to Dr. Crystal's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, the Company will cover the portion of the premium amount equal to the amount that it would have paid to provide health insurance to Dr. Crystal had he remained employed with us until the earliest of (A) 12 months following termination, (B) Dr. Crystal's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Dr. Crystal's COBRA health continuation period, and (v) he will be entitled to acceleration of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by Dr. Crystal.

***Douglas Barry***

Under Mr. Barry's employment agreement, or the Barry Employment Agreement, Mr. Barry serves as our Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary on an at-will basis. Mr. Barry's annual base salary is subject to periodic review and adjustment by the compensation committee, and he is eligible to earn an annual bonus with a target amount expressed as a percentage of his base salary, which target amount is set annually by the compensation committee. Mr. Barry is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.

Pursuant to the Barry Employment Agreement, in the event that Mr. Barry's employment is terminated by us without "cause" or Mr. Barry resigns for "good reason" (as each term is defined in the Barry Employment Agreement), subject to his execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) he will be entitled to receive base salary continuation for six months following termination, and (ii) subject to Mr. Barry's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Mr. Barry had he remained employed with us until the earliest of (A) six months following termination, (B) Mr. Barry's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Mr. Barry's COBRA health continuation period.

In lieu of the payments and benefits described in the preceding sentence, in the event that Mr. Barry's employment is terminated by us without cause or Mr. Barry resigns for good reason on or within 12 months following a "change in control" (as defined in the Barry Employment Agreement), subject to his execution and the effectiveness of a separation agreement, including a general release of claims in our favor, (i) he will be entitled to receive a lump sum in cash equal to nine months of his then-current annual base salary (or Mr. Barry's annual base salary in effect immediately prior to the change in control, if higher), (ii) he will be entitled to receive a lump sum in cash equal to his target annual cash incentive compensation for the year of termination, (iii) subject to Mr. Barry's copayment of premium amounts at the applicable active employees' rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Mr. Barry had he remained employed with us until the earliest of (A) nine months following termination, (B) Mr. Barry's eligibility for group medical plan benefits under any other employer's group medical plan or (C) the end of Mr. Barry's COBRA health continuation period, and (iv) he will be entitled to acceleration of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by him.

### **Potential Payments Upon Termination or Change in Control**

The amount of compensation and benefits payable to each named executive officer under our employment agreements in various termination and/or change-in-control situations has been estimated in the table below, which assumes that such termination and/or change-in-control occurred on December 31, 2024 and that no noncompetition-related payments will be made following any such termination. Such compensation and benefits amounts were calculated based on employment agreements in effect on December 31, 2024. The value of the equity vesting acceleration was calculated based on the assumption that the change-in-control and/or the executive's employment termination occurred on December 31, 2024. For purposes of the following table, we have used \$3.09 per share, which was the closing price of our common stock as reported on the Nasdaq Global Select Market on December 31, 2024, the last trading day of the year 2024, to estimate the value of our common stock upon acceleration. The value of the option vesting acceleration was calculated by multiplying the number of unvested shares underlying stock options subject to vesting acceleration as of December 31, 2024 by the difference between the closing price of our common stock as reported on the Nasdaq Global Select Market on December 31, 2024 and the exercise price for such unvested stock options. The value of the RSU vesting acceleration was calculated by multiplying the number of unvested RSUs subject to vesting acceleration as of December 31, 2024 by the closing price of our common stock as reported on the Nasdaq Global Select Market on December 31, 2024.

Name	Benefit	Triggering Event			
		Resignation for Good Reason or Termination Without Cause Outside of 12 Months of the Change in Control Period (\$)	Resignation for Good Reason or Termination Without Cause Within 12 Months of the Change in Control Period (\$)		
Barbara Weber, M.D. <i>President, Chief Executive Officer and Director</i>	Severance payments	660,000	(1)	990,000	(2)
	Cash incentive payments	396,000	(3)	594,000	(4)
	Health care continuation	17,029	(5)	25,544	(6)
	Acceleration of equity award vesting	182,013	(7)	895,312	(8)
	<b>Total</b>	<b>1,255,042</b>		<b>2,504,856</b>	
Daniella Beckman <i>Chief Financial Officer</i>	Severance payments	486,314	(1)	486,314	(1)
	Cash incentive payments	194,526	(3)	194,526	(3)
	Health care continuation	24,137	(5)	24,137	(5)
	Acceleration of equity award vesting	-		298,358	(8)
	<b>Total</b>	<b>704,977</b>		<b>1,003,335</b>	
Adam Crystal, M.D., Ph.D. <i>President of Research and Development</i>	Severance payments	569,250	(1)	569,250	(1)
	Cash incentive payments	256,163	(3)	256,163	(3)
	Health care continuation	-	(5)	-	(5)
	Acceleration of equity award vesting	-		532,436	(8)
	<b>Total</b>	<b>825,413</b>		<b>1,357,849</b>	
Douglas Barry <i>Chief Legal Officer</i>	Severance payments	225,600	(4)	338,400	(5)
	Cash incentive payments	-		180,480	(3)
	Health care continuation	12,069	(9)	18,103	(10)
	Acceleration of equity award vesting	-		233,967	(8)
	<b>Total</b>	<b>237,669</b>		<b>770,950</b>	

- (1) Represents continued base salary in an amount equal to twelve (12) months of the named executive officers annual base salary in effect as of December 31, 2024.
- (2) Represents continued base salary in an amount equal to eighteen (18) months of the named executive officers annual base salary in effect as of December 31, 2024.
- (3) Represents a lump sum in cash in an amount equal to 1 times the named executive officers target annual cash incentive compensation in effect as of December 31, 2024.
- (4) Represents a lump sum in cash in an amount equal to 1.5 times the named executive officers target annual cash incentive compensation in effect as of December 31, 2024.
- (5) Represents the aggregate of monthly cash payments for twelve (12) months for continued medical and dental benefits for the named executive officer.
- (6) Represents the aggregate of monthly cash payments for eighteen (18) months for continued medical and dental benefits for the named executive officer.
- (7) Represents the acceleration of vesting of twelve (12) months of the unvested stock options and other stock-based awards subject solely to time-based vesting held by the named executive officer on December 31, 2024.
- (8) Represents the acceleration of vesting of 100% of the unvested stock options and other stock-based awards subject solely to time-based vesting held by the named executive officer on December 31, 2024.
- (9) Represents the aggregate of monthly cash payments for six (6) months for continued medical and dental benefits for the named executive officer.
- (10) Represents the aggregate of monthly cash payments for nine (9) months for continued medical and dental benefits for the named executive officer.

### CEO Pay Ratio

As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of our employees to the annual total compensation of Barbara Weber, M.D., our current President and Chief Executive Officer.

#### Pay Ratio

For the Fiscal Year 2024:

- The total annual total compensation of our median employee, other than our principal executive officer, was \$294,361.
- Dr. Weber's annual total compensation, as reported in the "Total" column of the "Summary Compensation Table," was \$6,541,200.

Based on this information, the ratio of the annual total compensation of Dr. Weber to the total annual compensation of the median employee other than Dr. Weber is approximately 22 to 1.

#### Identification of Median Employee

The Company selected December 31, 2024, the last day of fiscal year 2024, as the date on which to determine its median employee. As of that date, we had 155 employees. For purposes of identifying the median employee, we considered the aggregate of the following compensation elements for each of its employees, as compiled from its internal records as of December 31, 2024:

- Earned base salary or base wages for the period beginning on January 1, 2024 and ending on December 31, 2024;
- Target bonuses for fiscal year 2024; and
- Target long-term equity awards.

We selected the above compensation elements because they represent its principal broad-based compensation elements. Because all of our employees are in the U.S., we did not make any cost-of-living adjustments or exclude any foreign jurisdictions in accordance with Item 402(u) of Regulation S-K. In determining the annual total compensation of the median employee, the employee's compensation was calculated in accordance with Item 402(c)(2)(x) of Regulation S-K, as required pursuant to the SEC executive compensation disclosure rules. This calculation is the same calculation used to determine total compensation for purposes of the Summary Compensation Table with respect to each of our NEOs.

This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described above. Because the SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee's annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.

#### Pay Versus Performance

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, Tango is providing the following information about the relationship between the executive compensation actually paid to our named executive officers and certain aspects of our financial performance. The following table sets forth the compensation for our Chief Executive Officer and the average compensation for our other named executive officers (Non-CEO NEOs), both as reported in the Summary Compensation Table and with certain adjustments to reflect the "Compensation Actually Paid", or CAP, to such individuals, as defined under SEC rules, for each of 2024, 2023, and 2022. The table also provides information on our cumulative total shareholder return, or TSR, the cumulative TSR of the Nasdaq Biotechnology Index and our Net Loss over such years in accordance with SEC rules. As a clinical stage biotech company, we do not use any financial performance measures in our compensation program or for comparison to any corporate goals. For further information concerning our pay for performance philosophy and how we align executive compensation with our performance, please refer to "Compensation Discussion and Analysis."

#### Pay Versus Performance Table

Year	Summary Compensation Table Total for Dr. Weber (\$)(1)	Compensation Actually Paid to Dr. Weber (\$)(2)(3)	Average Summary Compensation Table Total for Non-PEO NEOs (\$)(4)	Average Compensation Actually Paid to Non-PEO NEOs (\$)(2)(3)(4)	Year-end Value of \$100 Invested on 12/31/2021 in:		
					TNGX (\$)	Nasdaq Biotechnology Index (\$)	Net Loss (\$ millions)
2024	6,541,200	(3,076,115)	3,012,686	(370,843)	28.2	93.5	(130.3)
2023	3,391,059	8,141,931	2,134,765	3,049,295	90.5	94.0	(101.7)
2022	4,681,787	(2,846,266)	1,667,890	(72,512)	66.3	89.9	(108.2)

(1) Barbara Weber, M.D., has served as the Company's PEO since March 2017.

(2) Deductions from, and additions to, total compensation in the Summary Compensation Table by year to calculate Compensation Actually Paid include:


	2024		2023		2022	
	Dr. Weber	Average Non-PEO NEOs	Dr. Weber	Average Non-PEO NEOs	Dr. Weber	Average Non-PEO NEOs
<b>Total Compensation from Summary Compensation Table</b>	<b>\$ 6,541,200</b>	<b>3,012,686</b>	<b>3,391,059</b>	<b>2,134,765</b>	<b>4,681,787</b>	<b>1,667,890</b>
<b>Adjustments for Equity Awards</b>						
Adjustment for grant date values in the Summary Compensation Table	\$ (5,415,711)	\$ (2,254,684)	\$ (2,351,247)	\$ (1,333,526)	\$ (3,740,625)	\$ (1,047,375)
Year-end fair value of unvested awards granted in the current year	\$ 986,795	\$ 410,826	\$ 5,056,057	\$ 2,353,493	\$ 2,465,703	\$ 690,397
Year-over-year difference of year-end fair values for unvested awards granted in prior years	\$ (4,053,246)	\$ (1,406,563)	\$ 2,709,513	\$ 263,334	\$ (3,614,250)	\$ (740,130)
Fair values at vest date for awards granted and vested in current year	\$ -	\$ -	\$ -	\$ 7,153	\$ -	\$ -
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years	\$ (1,135,153)	\$ (133,108)	\$ (663,451)	\$ (116,446)	\$ (2,638,881)	\$ (643,294)
Forfeitures during current year equal to prior year-end fair value	\$ -	\$ -	\$ -	\$ (259,478)	\$ -	\$ -
<b>Total Adjustments for Equity Awards</b>	<b>\$ (9,617,316)</b>	<b>\$ (3,383,529)</b>	<b>\$ 4,750,872</b>	<b>\$ 914,530</b>	<b>\$ (7,528,053)</b>	<b>\$ (1,740,402)</b>
<b>Compensation Actually Paid (as calculated)</b>	<b>\$ (3,076,115)</b>	<b>\$ (370,843)</b>	<b>\$ 8,141,931</b>	<b>\$ 3,049,295</b>	<b>\$ (2,846,266)</b>	<b>\$ (72,512)</b>

- (3) The following summarizes the valuation assumptions used for stock option awards included as part of Compensation Actually Paid:
- Expected life of each stock option is based on the "simplified method" using an average of the remaining vest and remaining term, as of the vest/FYE date.
  - Strike price is based on each grant date closing price and asset price is based on each vest/FYE closing price.
  - Risk free rate is based on the Treasury Constant Maturity rate closest to the remaining expected life as of the vest/FYE date.
  - Historical volatility is based on daily price history for each expected life (years) prior to each vest/FYE date. Closing prices provided by S&P Capital IQ are adjusted for dividends and splits.
  - Represents annual dividend yield on each vest/FYE date.
- (4) Non-CEO NEOs reflect the average Summary Compensation Table total compensation and average Compensation Actually Paid for the following executives by year:
- 2024: Daniella Beckman, Adam Crystal, M.D., Ph.D., & Douglas Barry  
2023: Daniella Beckman, Adam Crystal, M.D., Ph.D., & Alan Huang, Ph.D.  
2022: Daniella Beckman & Alan Huang, Ph.D.


#### Relationship between Compensation Actually Paid and Company Performance Measures

The following charts show the relationships over the past three years of the CAP for our CEO and Non-CEO NEOs as compared to our cumulative TSR, the cumulative NASDAQ Biotechnology Index TSR, and our net loss.

#### CAP vs TSR



### CAP vs Net Loss



## NON-EMPLOYEE DIRECTOR COMPENSATION

We have adopted an amended and restated non-employee director compensation policy under which each non-employee director receives the following amounts for his or her services on our board of directors.

- A stock option to purchase 60,000 shares of our common stock and an RSU award covering 10,000 shares of our common stock upon the director's initial election or appointment to our board of directors. The stock options vest over 36 substantially equal monthly installments over three years from the date of grant and the RSUs vest in three equal annual installments over three years from the date of grant (the specific vesting dates are established by the compensation committee), in each case subject to continued service as a director through the applicable vesting date.
- An annual option to purchase 37,500 shares of our common stock and an RSU award covering 6,250 shares of our common stock on the date of the annual meeting for such year. The annual option award vests in 12 substantially equal monthly installments over one year from the date of grant and the annual RSU award vests in its entirety on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders, in each case subject to continued service as a director through the applicable vesting date. Directors who were elected in the 12 months preceding the annual grant receive a pro-rated portion of the annual stock option grant and RSU award based on the number of months of time in service on the board.
- An annual director fee of \$40,000.
- If the director serves on a committee of our board of directors or in the other capacities stated below, an additional annual fee as follows:
  - Non-executive chairperson, \$30,000
  - Lead independent director, \$15,000
  - Audit committee chairperson, \$15,000
  - Audit committee member, \$7,500
  - Compensation committee chairperson, \$12,000
  - Compensation committee member, \$6,000
  - Nomination and governance committee chairperson, \$10,000
  - Nomination and governance committee member, \$5,000

Options granted to our non-employee directors under the non-employee director compensation policy have an exercise price equal to the fair market value of our common stock on the date of grant and will expire not later than ten years after the date of grant. All unvested options and RSU awards held by non-employee members of the board of directors vest in full upon the occurrence of a change in control.

In May 2024, the compensation committee revised the non-employee director compensation policy as follows:

- The annual cash retainer payable to the non-executive compensation committee chairperson be increased from \$10,000 to \$12,000.
- The annual cash retainer payable to the non-executive compensation committee member be increased from \$5,000 to \$6,000.
- The annual cash retainer payable to the non-executive nomination and governance committee chairperson be increased from \$8,000 to \$10,000.
- The annual cash retainer payable to the non-executive nomination and governance committee member be increased from \$4,000 to \$5,000.

In 2024, the board of directors, based on the recommendation of the compensation committee, amended the non-employee director compensation policy to increase the number of: (i) shares underlying stock options granted to non-employee directors from 30,000 to 37,500; and (ii) RSUs granted to non-employee directors from 5,000 to 6,250 RSUs. This increase was approved by the board of directors to align director equity compensation with the median equity compensation paid to non-employee directors at our peer companies.

### ***2024 Non-Employee Director Compensation Table***

The table below shows the cash fees paid to our non-employee directors in connection with their service on our board of directors, and the stock option awards and RSUs granted to our non-employee directors, during the fiscal year ended December 31, 2024.

Name	Fees Earned or Paid In Cash \$(1)	Stock Awards \$(2)(3)	Option Awards \$(2)(3)	Total (\$)
Alexis Borisy	77,500	46,313	194,588	318,401
John Ketchum(4)	45,750	34,738	145,941	226,429
Kanishka Pothula(5)	—	—	—	—
Lesley Ann Calhoun	59,750	46,313	194,588	300,651
Mace Rothenberg, M.D.	55,250	46,313	194,588	296,151
Malte Peters, M.D.	51,500	46,313	194,588	292,401

- (1) Amounts represent cash compensation earned and paid pursuant to our amended and restated non-employee director compensation policy.
- (2) The amounts reported represent the aggregate grant-date fair value of stock options and RSUs awarded to our non-employee directors in 2024, calculated in accordance with ASC Topic 718, disregarding the effect of estimated forfeitures related to service-based vesting. See Note 2 and Note 11 to our audited financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on February 27, 2025 for a discussion of assumptions made in determining the aggregate grant date fair value of stock option and RSU awards. The amounts presented do not correspond to the actual value that may be recognized by the applicable director upon vesting or exercise of the stock options or the sale of the shares of common stock underlying such stock options or the vesting of RSUs and the sale of the shares received upon the vesting of the RSUs.
- (3) The table below shows the aggregate number of shares underlying stock option awards (exercisable and unexercisable) and unvested RSUs held as of December 31, 2024 by each non-employee director who served as a non-employee director during the year ended December 31, 2024:

Name	Option Awards	Stock Awards
	Shares Subject to Outstanding Options	Shares Subject to Outstanding RSUs
Alexis Borisy	238,963	6,250
John Ketchum	88,125	11,355
Kanishka Pothula	—	—
Lesley Ann Calhoun	192,425	6,250
Mace Rothenberg, M.D.	192,425	6,250
Malte Peters, M.D.	226,395	6,250

- (4) Mr. Ketchum was elected as a member of the board of directors on August 29, 2023 and thus received a pro-rated portion of the annual stock option grant and RSU award based on the number of months of time in service on the board per the non-employee director compensation policy above.
- (5) Mr. Pothula has waived cash and equity compensation retainers for services on the board of directors.

## REPORT OF THE COMPENSATION COMMITTEE

*The information contained in this report shall not be deemed to be “soliciting material,” to be “filed” with the SEC, or to be subject to Regulation 14A or Regulation 14C (other than as provided in Item 407 of Regulation S-K) or to the liabilities of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed to be incorporated by reference in future filings with the SEC except to the extent that Tango specifically incorporates it by reference into a document filed under the Securities Act or the Exchange Act.*

April 21, 2025

Our executive compensation program is administered by the Compensation Committee, which is composed entirely of independent, non-employee directors and is responsible for approving and reporting to our Board of Directors on all elements of compensation for our executive officers. In this regard, the Compensation Committee has reviewed and discussed the “Compensation Discussion and Analysis” section of this Proxy Statement with management. Based on this review and discussion, the Compensation Committee recommended to our Board of Directors that the “Compensation Discussion and Analysis” section be included in this Proxy Statement and incorporated by reference into our 2024 Annual Report on Form 10-K.

Submitted by:  
**Compensation Committee**  
Malte Peters (*Chairman*)  
John Ketchum  
Mace Rothenberg

### **PROPOSAL NO. 2 – RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025**

We have selected PricewaterhouseCoopers LLP as the independent registered public accounting firm to perform the audit of our consolidated financial statements for the fiscal year ending December 31, 2025, and we are asking you and other stockholders to ratify this selection. PricewaterhouseCoopers LLP has audited our financial statements since 2017 (serving as Tango's independent registered public accounting firm prior to the Business Combination).

The audit committee annually reviews the independent registered public accounting firm's independence, including reviewing all relationships between the independent registered public accounting firm and us and any disclosed relationships or services that may impact the objectivity and independence of the independent registered public accounting firm, and the independent registered public accounting firm's performance. As a matter of good corporate governance, the audit committee and the board of directors determined to submit to stockholders for ratification the appointment of PricewaterhouseCoopers LLP. The majority of the votes properly cast is required in order to ratify the appointment of PricewaterhouseCoopers LLP. In the event that a majority of the votes properly cast do not ratify this appointment of PricewaterhouseCoopers LLP, the audit committee will consider this fact when it appoints the independent registered public accounting firm for the fiscal year ending December 31, 2025. Even if the appointment of PricewaterhouseCoopers LLP is ratified, the audit committee retains the discretion to appoint a different independent registered public accounting firm at any time if it determines that such a change is in the interests of the Company.

We expect that a representative of PricewaterhouseCoopers LLP will attend the Annual Meeting and the representative will have an opportunity to make a statement if he or she so chooses. The representative will also be available to respond to appropriate questions from stockholders.

#### **Vote Required and Board of Directors' Recommendation**

Approval of this proposal requires the affirmative vote of a majority of the votes properly cast for and against such matter. You may vote “FOR,” “AGAINST” or “ABSTAIN” from voting on this proposal. Abstentions and broker “non-votes,” if any, will have no effect on the outcome of this proposal.

**The board of directors recommends voting “FOR” Proposal No. 2 to ratify the appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending December 31, 2025.**

## PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table sets forth the fees of PricewaterhouseCoopers LLP billed to us for each of the last two fiscal years for audit services and billed to us in each of the last two fiscal years for other services. The audit committee approved 100% of the services set forth below.

Fee Category	2024	2023
Audit Fees	\$ 1,047,214	\$ 800,000
Audit-Related Fees	—	—
Tax Fees	—	—
All Other Fees	2,125	4,409
<b>Total Fees</b>	<b>\$ 1,049,339</b>	<b>\$ 804,409</b>

*Audit Fees.* Audit fees consist of fees billed for the audit of our annual consolidated financial statements, review of the interim consolidated financial statements, and the review of registration statements.

*Tax Fees.* Tax fees consist of aggregate fees for tax compliance and tax analysis related services.

*All Other Fees.* All other fees consist of fees for accounting research tools.

### Audit Committee Pre-Approval Policy and Procedures

The audit committee has adopted a policy, or the Pre-Approval Policy, that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage PricewaterhouseCoopers LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the audit committee, or specific pre-approval, or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy, or general pre-approval. Unless a type of service to be provided by PricewaterhouseCoopers LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the audit committee or by a designated member of the audit committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the audit committee will consider whether such services are consistent with the SEC's rules on auditor independence. The audit committee will also consider whether the independent auditor is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company's business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company's ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. On an annual basis, the audit committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that may be provided by PricewaterhouseCoopers LLP without first obtaining specific pre-approval from the audit committee. The audit committee may revise the list of general pre-approved services from time to time, based on subsequent determinations.

## REPORT OF THE AUDIT COMMITTEE

This report is submitted by the audit committee of the board of directors (the "Board") of Tango Therapeutics, Inc. (the "Company"). The audit committee consists of the three directors whose names appear below. None of the members of the audit committee is an officer or employee of the Company, and the board has determined that each member of the audit committee is "independent" for audit committee purposes as that term is defined under Rule 10A-3 of the Exchange Act, and the applicable rules of the Nasdaq Stock Market LLC ("Nasdaq"). Each member of the audit committee meets the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. The board has designated Ms. Calhoun as an "audit committee financial expert," as defined under the applicable rules of the SEC. The audit committee operates under a written charter adopted by the board.

The audit committee's general role is to assist the Board in monitoring our financial reporting process and related matters. Its specific responsibilities are set forth in its charter.

The audit committee has reviewed the Company's consolidated financial statements for 2024 and met with management, as well as with representatives of PricewaterhouseCoopers LLP, the Company's independent registered public accounting firm, to discuss the consolidated financial statements. The audit committee also discussed with members of PricewaterhouseCoopers LLP the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and the U.S. Securities and Exchange Commission.

In addition, the audit committee received the written disclosures and the letter from PricewaterhouseCoopers LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant's communications with the audit committee concerning independence, and discussed with members of PricewaterhouseCoopers LLP its independence from the Company.

Based on these discussions, the financial statement review and other matters it deemed relevant, the audit committee recommended to the Board that the Company's audited consolidated financial statements be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

The information contained in this audit committee report shall not be deemed to be "soliciting material," "filed" or incorporated by reference into any past or future filing under the Securities Exchange Act of 1934 or the Securities Act of 1933 unless and only to the extent that the Company specifically incorporates it by reference.

Audit Committee of the Board of Directors of Tango Therapeutics, Inc.  
*Lesley Ann Calhoun (Chairman)*  
*Kanishka Pothula*  
*Alexis Borisy*

**PROPOSAL NO. 3 – AMENDMENT OF OUR SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED TO DATE, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 200,000,000 TO 400,000,000**

Our Second Amended and Restated Certificate of Incorporation, as amended to date, or charter, currently authorizes the issuance of 200,000,000 shares of common stock. In April 2025, our board of directors declared it advisable and approved and adopted an amendment, subject to approval and adoption by our stockholders, to our charter, to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000, or the Charter Amendment. Our board of directors is requesting stockholder approval of the Charter Amendment.

The additional common stock to be authorized by adoption of the Charter Amendment would have rights identical to our currently outstanding common stock. Adoption of the Charter Amendment and issuance of additional common stock would not affect the rights of the holders of our currently outstanding common stock. If the Charter Amendment is adopted, it will become effective upon filing of a Certificate of Amendment of our Second Amended and Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware, which we currently plan to file promptly following the Annual Meeting if this proposal is approved. The remainder of our charter will remain unchanged after effectiveness of the Charter Amendment.

Our board of directors believes that additional authorized shares of common stock would give us the necessary flexibility to issue shares for various corporate purposes, including, in particular, raising capital, and enable us to take timely advantage of market conditions and opportunities. Other corporate purposes for which the additional authorized shares could be used include, but are not limited to, potential strategic transactions, including mergers, acquisitions, and other business combinations; future grants and awards under equity compensation plans; stock splits and dividends; and other general corporate working capital needs. We currently do not have any specific plans, arrangements or understandings to issue additional shares of our common stock, except for (i) the issuance of shares of common stock pursuant to our equity incentive plans and (ii) potential issuances pursuant to our sales agreement with Jefferies LLC, through which we may offer and sell shares of our common stock from time to time in “at-the-market” offerings. Having additional authorized shares available will provide additional flexibility to use our common stock for business and financial purposes in the future as well as to have sufficient shares available to provide appropriate equity incentives for our employees. The additional shares may be used for various purposes without further stockholder approval, except as may be required in certain cases by law or the Nasdaq rules.

As of April 8, 2025, our common stock share utilization was approximately as follows:

	<b><u>Number of Shares of Common Stock</u></b>
Authorized for issuance	200,000,000
Issued and outstanding	108,107,890
Reserved for issuance	
• <i>Available for future grant under employee equity incentive plans</i>	13,536,579
• <i>Outstanding awards under our employee equity incentive plans</i>	25,305,449
• <i>Pre-funded warrants (unexercised)</i>	<u>2,340,579</u>
Total share usage (issued and outstanding + reserved for issuance)	149,290,497
Shares available for issuance	50,709,503
Total share usage as a percentage of authorized	74.65%

**Form of Amendment**

If the stockholders approve this proposal, our charter will be amended to increase the number of shares of common stock the Company is authorized to issue from 200,000,000 shares to 400,000,000 shares. The par value of the common stock will remain at \$0.001 per share. There will be no change to the number of authorized shares of undesignated preferred stock. The Certificate of Amendment would amend the first paragraph of ARTICLE IV of the charter in its entirety to read as follows:

"The total number of shares of capital stock which the Corporation shall have authority to issue is four hundred and ten million (410,000,000), of which (i) four hundred million (400,000,000) shares shall be a class designated as common stock, par value \$0.001 per share (the “Common Stock”), and (ii) ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value \$0.001 per share (the “Undesignated Preferred Stock”)."

The remaining text of ARTICLE IV of the charter will remain unchanged. The complete text of the Charter Amendment is attached to this Proxy Statement as Annex A.

### **Potential Anti-takeover Effects**

Release No. 34-15230 of the staff of the SEC requires disclosure and discussion of the effects of any action that may be used as an anti-takeover mechanism. Although not a factor in the decision by our Board to effect the increase of our authorized shares of common stock, one of the effects of having increased additional shares of our authorized common stock available for issuance may be to enable the board to render more difficult or to discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest, or otherwise, and thereby protect the continuity of then-present management. Unless prohibited by the regulations of applicable law or other agreements or restrictions, a sale of shares of common stock by us or other transactions in which the number of our outstanding shares of common stock would be increased could dilute the interest of a party attempting to obtain control of us. By potentially discouraging initiation of any such unsolicited takeover attempts, the Charter Amendment may limit the opportunity for our stockholders to dispose of their shares at the higher price generally available in takeover attempts or that may be available under a merger proposal.

The Charter Amendment is not being proposed in response to any effort of which we are aware to accumulate shares of common stock or obtain control of the Company. While it is possible that our management could use the Charter Amendment to resist or frustrate a third-party transaction that is favored by a majority of stockholders, we have no current intent or plans to employ the Charter Amendment as an anti-takeover device and do not have any plans or proposals to adopt any other provisions or enter into other arrangements that may have material anti-takeover consequences.

### **Interests of Directors and Executive Officers**

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our common stock.

### **Vote Required and Board of Directors' Recommendation**

Approval of this proposal requires the affirmative vote of a majority of the votes cast. You may vote "FOR," "AGAINST" or "ABSTAIN" from voting on this proposal. Abstentions and broker non-votes, if any, will have no effect on the outcome of the proposal.

**The board of directors recommends voting "FOR" Proposal No. 3 to approve an amendment to our Second Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000**

## **PROPOSAL NO. 4 – NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS**

In prior years, we were an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended; therefore, we were not required to hold a non-binding advisory vote to approve the compensation of our named executive officers, commonly known as a “Say-on-Pay” vote. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and Section 14A of the Exchange Act, our stockholders are entitled to vote in such Say-on-Pay vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in this proxy statement at least once every three years. Although this is a non-binding advisory vote, because we value the opinion of our stockholders, our board of directors and our compensation committee will consider the outcome of the “Say-on-Pay” vote described in this Proposal No. 3 and the related “Say-on-Frequency” vote described in Proposal 5 of this proxy statement at the Annual Meeting, as well as feedback received throughout the year, when making compensation determinations for our executive officers in the future.

This vote is not intended to address any specific item of compensation, but rather the overall compensation our named executive officers and the compensation philosophy, policies and practices described in this proxy statement. The compensation of our named executive officers subject to the vote is disclosed under the “Compensation Discussion and Analysis” section, the compensation tables, and related narrative disclosure that accompanies the compensation tables contained in this proxy statement. As discussed in those disclosures, we believe that our compensation policies and decisions are designed to reward performance, are strongly aligned with our stockholders’ interests and are consistent with current market practices. Compensation of our named executive officers is designed to enable us to attract, motivate, and retain talented and experienced executives to lead us successfully in a competitive environment. Accordingly, we are asking our stockholders to cast a non-binding, advisory vote FOR the following resolution:

**RESOLVED**, that the compensation of our named executive officers, as disclosed pursuant to the rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and related narrative disclosures contained in this proxy statement, is hereby APPROVED.

This vote is advisory, and therefore not binding on us, the board of directors, or our compensation committee. However, our board of directors and compensation committee value your opinion and intend to consider the outcome of the vote when making compensation decisions in the future.

### **Vote Required and Board of Directors’ Recommendation**

A majority of the votes properly cast FOR this proposal is required to approve, on a non-binding, advisory basis, the 2024 compensation of our named executive officers. Shares that are voted “abstain” and broker non-votes, if any, will have no effect on the outcome of this proposal.

**The board of directors unanimously recommends voting “FOR” Proposal No. 4 to approve, on a non-binding, advisory basis, the compensation of our named executive officers.**

**PROPOSAL NO. 5 – NON-BINDING, ADVISORY VOTE ON THE FREQUENCY OF FUTURE NON-BINDING, ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS**

The Dodd-Frank Act and Section 14A of the Exchange Act provide that stockholders must be given the opportunity to vote, on a non-binding, advisory basis, for their preference as to how frequently we should hold future Say-on-Pay votes. We are required to solicit stockholder votes on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers at least once every six years. This is commonly known as a “Say-on-Frequency” proposal. We are asking our stockholders whether our future Say-on-Pay votes should occur every one, two, or three years. Stockholders may also abstain from voting.

The vote on this proposal is advisory; therefore, it is not binding on the Company, our board of directors or our compensation committee. We may determine in the future that it is in the best interests of the Company and our stockholders to hold Say-on-Pay votes more or less frequently than the frequency indicated by stockholders in voting on this proposal or as currently recommended by our board of directors. However, we plan to consider the results of the vote on this proposal in determining the frequency of our Say-on-Pay votes because we value the opinions of our stockholders.

Currently, we believe that it is in the best interests of the Company and our stockholders to hold a Say-on-Pay vote every year, and this is the frequency recommended by our board of directors. We believe this frequency will enable our stockholders to vote, on a non-binding, advisory basis, on our most recent executive compensation practices and decisions as presented in our annual proxy statements, which will lead to greater transparency and more meaningful and timely communication between the Company and our stockholders regarding the compensation of our named executive officers. Accordingly, we ask our stockholders to indicate their preferred voting frequency by voting for every “one year,” “two years,” or “three years” (or abstaining from voting) in response to the following resolution at the Annual Meeting:

**RESOLVED**, that the alternative of every one year, two years, or three years that receives the highest number of affirmative votes cast by stockholders in person or by proxy at this meeting will be deemed the preferred frequency with which the Company is to hold future non-binding, advisory votes on the compensation of the Company’s named executive officers.

**Vote Required and Board of Directors’ Recommendation**

Stockholders will not be voting to approve or disapprove of the recommendation of our board of directors. The proxy card provides stockholders with the opportunity to choose among four options with respect to this proposal (holding the vote every one, two, or three years, or abstaining). The option that receives the highest number of affirmative votes properly cast will be deemed to be the frequency preferred by our stockholders. Shares that are voted “abstain” and broker non-votes, if any, will have no effect on the outcome of this proposal.

**The board of directors unanimously recommends a vote, on a non-binding, advisory basis, for “ONE YEAR” as the preferred frequency for future non-binding advisory votes on the compensation of our named executed officers.**

## SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

### Security Ownership of Certain Beneficial Owners and Management

The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our common stock as of April 1, 2025 by:

- each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of Tango’s outstanding common stock;
- each of Tango’s named executive officers and directors; and
- all of Tango’s executive officers and directors as a group.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options or the vesting of RSUs, within 60 days of April 1, 2025. Shares subject to RSU awards that vest within 60 days of April 1, 2025, are considered outstanding and beneficially owned by the person holding such options or RSU awards for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, based on the information provided to us, we believe that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise noted, the business address of each of our directors and executive officers is 201 Brookline Avenue, Suite 901, Boston, MA 02215. The percentage of beneficial ownership is calculated based on 108,107,890 shares of common stock outstanding as of April 1, 2025.

Name and Address of Beneficial Owner	Number of Shares	%
<b>Named Executive Officers and Directors:</b>		
Barbara Weber, M.D.(1)	5,123,715	4.7
Daniella Beckman(2)	1,163,421	1.1
Alexis Borisy(3)	240,838	*
Malte Peters, M.D.(4)	228,270	*
Lesley Ann Calhoun(5)	189,300	*
Mace Rothenberg, M.D.(6)	194,300	*
John Ketchum(7)	64,114	*
Kanishka Pothula(8)	-	*
Adam Crystal, M.D., Ph.D.(9)	442,940	*
Douglas Barry(10)	449,024	*
Executive Officers and Directors as a group (10 individuals)	8,095,922	7.5
<b>5% Stockholders:</b>		
Third Rock Ventures IV, L.P.(11)	16,859,075	15.6
Entities affiliated with Boxer Capital, LLC(12)	10,707,885	9.9
EcoR1 Capital, LLC(13)	10,620,736	9.8
TCG Crossover II(14)	10,500,612	9.7
Nextech Invest, Ltd.(15)	5,533,980	5.1

\* Less than one percent.

- (1) Consists of 1,456,344 shares of common stock and options to purchase 3,667,371 shares of common stock exercisable within 60 days of April 1, 2025.
- (2) Consists of 98,898 shares of common stock and options to purchase 1,064,523 shares of common stock exercisable within 60 days of April 1, 2025.
- (3) Consists of 5,000 shares of common stock and options to purchase 235,838 shares of common stock exercisable within 60 days of April 1, 2025.
- (4) Consists of 5,000 shares of common stock and options to purchase 223,270 shares of common stock exercisable within 60 days of April 1, 2025.
- (5) Consists of options to purchase 189,300 shares of common stock exercisable within 60 days of April 1, 2025.
- (6) Consists of 5,000 shares of common stock and options to purchase 189,300 shares of common stock exercisable within 60 days of April 1, 2025.

- (7) Consists of 3,333 shares of common stock and options to purchase 60,781 shares of common stock exercisable within 60 days of April 1, 2025.
- (8) Mr. Pothula has waived all equity or cash compensation for service as a non-employee director.
- (9) Consists of 69,700 shares of common stock and options to purchase 373,240 shares of common stock exercisable within 60 days of April 1, 2025.
- (10) Consists of 23,551 shares of common stock and options to purchase 425,473 shares of common stock exercisable within 60 days of April 1, 2025.
- (11) This information is solely based on a Form 4 filed by Third Rock Ventures IV, L.P. (“TRV IV”), Third Rock Ventures GP IV, L.P. (“TRV GP IV”) and TRV GP IV, LLC (“TRV GP IV LLC”, and collectively with TRV IV and TRV GP IV, the “Reporting Persons”) with the SEC on September 17, 2024. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV, LLC. Abbie Celniker, Ph.D., Robert Tepper, M.D., Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV GP IV, LLC who collectively make voting and investment decisions with respect to shares held by TRV IV L.P. The address for each of the Reporting Persons is 201 Brookline Ave, Suite 1401, Boston, MA 02215.
- (12) This information is solely based on a Schedule 13D/A filed by Boxer Capital Management, LLC (“Boxer Capital Management”), BCTG Holdings, LLC (“BCTG Holdings”), MVA Investors, LLC (“MVA Investors together with Boxer Capital, BCTG Holdings, and Aaron Davis, the “Reporting Persons”) with the SEC on January 2, 2025. Consists of 326,886 shares beneficially owned by MVA Investors and 10,380,999 shares beneficially owned by Boxer Capital Management. Aaron Davis has shared voting and dispositive power over the shares owned by MVA Investors and Boxer Capital Management. Aaron Davis serves as the Chief Executive Officer of MVA Investors. Each of the individuals and entities listed above expressly disclaims beneficial interest of the shares listed above except to the extent of any pecuniary interest therein. The principal business address of the Reporting Persons is: 12860 El Camino Real, Suite 300, San Diego, CA 92130.
- (13) This information is solely based on a Schedule 13G/A filed by EcoR1 Capital, LLC (“EcoR1”), EcoR1 Capital Fund Qualified, L.P. (“EcoR1 Capital”) and Oleg Nodelman (collectively, the “Reporting Persons”) with the SEC on February 14, 2025. The general partner of EcoR1 Capital is EcoR1. The manager of EcoR1 is Oleg Nodelman. Each of the individuals and entities listed above expressly disclaims beneficial interest of the shares listed above except to the extent of any pecuniary interest therein. The address for each Reporting Persons is 357 Tehama Street #3, San Francisco, CA 94103.
- (14) This information is solely based on a Schedule 13 filed by TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC (collectively, the “Reporting Persons”) with the SEC on November 20, 2024. These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.
- (15) This information is solely based on a Schedule 13G filed by Nextech Crossover I SCSp (“Nextech”), Nextech Crossover I GP S. à r.l. (“Nextech S. à r.l.”), Ian Charoub, Costas Constantinides and Rocco Sgobbo (collectively with Nextech and Nextech S. à r.l., the “Reporting Persons”) with the SEC on August 21, 2023. The general partner of Nextech is Nextech S. à r.l. Ian Charoub, Costas Constantinides and Rocco Sgobbo are members of the board of managers of Nextech S. à r.l. and share voting and dispositive power over the shares held by Nextech, and may be deemed to own beneficially the shares held by Nextech. The address for each of the Reporting Persons is 8 rue Lou Hemmer L-1748 Luxembourg-Findel Grand-Duché de Luxembourg.

## CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following is a description of transactions or series of similar transactions since January 1, 2024 (other than the compensation agreements and other arrangements described under the sections entitled “Executive Compensation” and “Director Compensation” in this proxy statement) to which:

- we were, or will be, a participant;
- the amount involved exceeded, or will exceed, \$120,000; and
- in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.

We believe that all of the transactions described below were made on terms no less favorable to us than could have been obtained from unaffiliated third parties.

### **Sesame Therapeutics, Inc.**

In June 2024, the Company and Sesame Therapeutics, Inc., or Sesame, entered into a license agreement, pursuant to which the Company granted a non-exclusive license to certain know-how associated with preclinical research. Pursuant to the license agreement, we received a \$100,000 upfront, non-refundable payment in June 2024 and are eligible to receive up to \$25.9 million in potential future clinical, regulatory, and commercial milestone payment events, as well as low single-digit tiered royalties on net sales of any product covered by a licensed patent. The transaction was deemed a related party transaction because Dr. Weber and Mr. Borisy are directors and equityholders in Sesame, and Nextech, an investment firm in which Mr. Pothula serves as a partner and of which Mr. Borisy is affiliated, holds an equity interest in Sesame. Pursuant to our Related Party Transaction Policy, the material facts as to the related parties' relationship and interest in the transaction were disclosed to the audit committee for consideration. However, because two of the three members of the audit committee had material interests in the proposed transaction, the remaining member of the audit committee recommended that the proposed transaction be considered by the full board of directors. The agreement was reviewed and approved by the non-interested members of our board of directors.

### **Revolution Medicines, Inc.**

In November 2024, the Company and Revolution Medicines, Inc., or RevMed, entered into a clinical trial collaboration and supply agreement. The agreement provides that RevMed will supply two of its RAS inhibitors at no cost to the Company for use in clinical trials that will include these combinations. The Company will be the sponsor of any combination trials and bear associated costs. Each company will retain commercial rights to its respective compounds, and the agreement is mutually non-exclusive. Due to common relationships amongst members of management and the boards of directors, this transaction is a related party transaction. The agreement was reviewed and approved by the non-interested members of our audit committee.

### **Aaron Davis**

In August 2024, the Company entered into a Consulting Agreement with Aaron Davis, the Managing Member of Boxer Capital Management, LLC, and a Tango director until August 2023. Boxer Capital Management has an investment management agreement with Boxer Capital. Boxer Capital is a former 10% holder of Tango common stock, but continues to hold in excess of 5% of Tango's outstanding common stock. In exchange for providing certain consulting services related to communications and investor relations messaging in connection with the public disclosure of Tango clinical trial programs and certain related matters, the Company issued Mr. Davis an option award to acquire 65,000 shares of common stock. The exercise price of the option was equal to the stock price on the date of grant. The agreement was reviewed and approved by the non-interested members of our audit committee.

### **Indemnification Agreements**

We are party to indemnity agreements with our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys' fees), judgments, fines and settlement amounts reasonably incurred by such persons in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our Company or that person's status as a member of our board of directors or as an executive officer to the maximum extent allowed under Delaware law.

### **Policies for Approval of Related Party Transactions**

Our audit committee reviews and approves transactions with directors, officers and holders of 5% or more our capital stock and their affiliates, or each, related party. Prior to the transaction, the material facts as to the related party's relationship or interest in the transaction are disclosed to our audit committee prior to their consideration of such transaction, and the transaction is not considered approved unless approved by the audit committee. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party's relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith.

#### *Policies and Procedures for Related Party Transactions*

We have adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions.

A "Related Person Transaction" is a transaction, arrangement or relationship in which we or any our subsidiaries was, is or will be a participant, the amount of which involved exceeds \$120,000, and in which any related person had, has or will have a direct or indirect material interest. A "Related Person" means:

- any person who is, or at any time during the applicable period was, one of our officers, directors or director nominee;
- any person who is known by us to be the beneficial owner of more than 5% of our voting stock;
- any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, daughter-in-law, brother-in-law or sister-in-law of a director, officer or a beneficial owner of more than 5% of its voting stock, and any person (other than a tenant or employee) sharing the household of such director, officer or beneficial owner of more than 5% of our voting stock; and
- any firm, corporation or other entity in which any of the foregoing persons is a partner or principal or in a similar position or in which such person has a 10% or greater beneficial ownership interest.

We have policies and procedures designed to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. The audit committee has the responsibility to review related party transactions.

## ADDITIONAL INFORMATION AND OTHER BUSINESS

### Householding

Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you upon written or oral request to Tango Therapeutics, Inc., 201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215, Attention: Corporate Secretary, telephone: (857) 320-4900. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and phone number.

### Stockholder Proposals

A stockholder who would like to have a proposal considered for inclusion in our 2026 proxy statement must submit the proposal in accordance with the procedures outlined in Rule 14a-8 so that it is received by us no later than December 22, 2025. In addition, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March 7, 2026. However, if the date of the 2026 Annual Meeting of Stockholders is changed by more than 30 days from the date of the previous year’s meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2026 Annual Meeting of Stockholders. SEC rules set standards for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement. Stockholder proposals should be addressed to Tango Therapeutics, Inc., 201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215, Attention: Corporate Secretary.

If a stockholder wishes to propose a nomination of persons for election to our board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder’s intention to bring such business before the meeting.

The required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the preceding year’s annual meeting, a stockholder’s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A) the 90th day prior to such annual meeting and (B) the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2026 Annual Meeting of Stockholders, the required notice must be received by our Corporate Secretary at our principal executive offices no earlier than February 5, 2026 and no later than March 7, 2026. Stockholder proposals and the required notice should be addressed to Tango Therapeutics, Inc., 201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215, Attention: Corporate Secretary.

### Other Matters

Our board of directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this proxy statement are properly brought before the meeting, the individuals named in the enclosed proxy intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment on those matters.

ANNEX A

AMENDMENT OF OUR COMPANY'S SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED TO DATE

CERTIFICATE OF AMENDMENT  
TO THE  
SECOND AMENDED AND RESTATED  
CERTIFICATE OF INCORPORATION  
OF  
TANGO THERAPEUTICS, INC.

(Pursuant to Section 242 of the  
General Corporation Law of the State of Delaware)

Tango Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), hereby certifies as follows:

1. The Corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware (the "DGCL") on May 21, 2020. An Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on September 2, 2020, as amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware on June 5, 2024 (the "Charter"). Pursuant to Section 242 of the DGCL, this Certificate of Amendment (this "Amendment") amends certain provisions of the Charter.

2. This Amendment has been approved and duly adopted by the Corporation's Board of Directors and stockholders in accordance with the provisions of Section 242 of the DGCL.

3. The first paragraph of Article IV of the Charter is hereby amended to read in its entirety as follows:

"The total number of shares of capital stock which the Corporation shall have authority to issue is four hundred and ten million (410,000,000), of which (i) four hundred million (400,000,000) shares shall be a class designated as common stock, par value \$0.001 per share (the "Common Stock"), and (ii) ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value \$0.001 per share (the "Undesignated Preferred Stock")."

IN WITNESS WHEREOF, this Amendment, having been duly adopted in accordance with Section 242 of the DGCL, has been duly executed by a duly authorized officer of the Corporation on this 5th day of June, 2025.

Tango Therapeutics, Inc.

By: \_\_\_\_\_  
Name: Barbara Weber, M.D.  
Title: President and Chief Executive Officer

TANGO THERAPEUTICS, INC.  
 201 BROOKLINE AVENUE, SUITE 901  
 BOSTON, MA 02215



**VOTE BY INTERNET**  
*Before The Meeting* - Go to [www.proxyvote.com](http://www.proxyvote.com) or scan the QR Barcode above

Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m. Eastern Time on June 4, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

*During The Meeting* - Go to [www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025)

You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.

**VOTE BY PHONE - 1-800-690-6903**

Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 p.m. Eastern Time on June 4, 2025. Have your proxy card in hand when you call and then follow the instructions.

**VOTE BY MAIL**

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:

V71874-P28493

KEEP THIS PORTION FOR YOUR RECORDS  
 DETACH AND RETURN THIS PORTION ONLY

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

**TANGO THERAPEUTICS, INC.**

The Board of Directors recommends you vote FOR the following:

1. Election of Class I Director

Company Nominee:

For Withhold

1a. Lesley Ann Calhoun

The Board of Directors recommends you vote FOR the following proposals:

For Against Abstain

2. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

3. To approve an amendment to our Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.

4. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

The Board of Directors recommends you vote 1 year on the following proposal:

1 Year 2 Years 3 Years Abstain

5. Non-binding, advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers.

**NOTE:** The Board of Directors will consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof.

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.

Signature [PLEASE SIGN WITHIN BOX] Date

Signature (Joint Owners) Date

**Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:**  
The Notice and Proxy Statement and Annual Report are available at [www.proxyvote.com](http://www.proxyvote.com).

V71875-P28493

**TANGO THERAPEUTICS, INC.**  
**Annual Meeting of Shareholders**  
**June 5, 2025 9:00 AM EDT**  
**This proxy is solicited by the Board of Directors**

The shareholder(s) hereby appoint(s) Barbara Weber, M.D., Daniella Beckman and Douglas Barry, or any of them, as proxies, each with the power to appoint his or her substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of TANGO THERAPEUTICS, INC. that the shareholder(s) is/are entitled to vote at the Annual Meeting of Shareholders to be held at 9:00 AM, EDT on June 5, 2025, virtually at [www.virtualshareholdermeeting.com/TNGX2025](http://www.virtualshareholdermeeting.com/TNGX2025), and any adjournment or postponement thereof.

**This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations.**

**Continued and to be signed on reverse side**

